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Preface to ”New Lipid Lowering Therapies for
Cardiovascular and Metabolic Diseases: Lessons from
the Past and Future Challenges”
This book illustrates some of the most recent research efforts that have been made in lowering
plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and
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Abstract: Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum
high-density lipoprotein cholesterol (HDL) cholesterol levels and decrease low-density lipoprotein
cholesterol (LDL) cholesterol concentration. However, three drugs of this class failed to show
a decrease of cardiovascular events in high-risk patients. A new CETP inhibitor, anacetrapib,
substantially increases HDL cholesterol and apolipoprotein (Apo) AI levels with a profound increase
of large HDL2 particles, but also pre-β HDL particles, decreases LDL cholesterol levels mainly due
to increased catabolism of LDL particles through LDL receptors, decreases lipoprotein a (Lp(a))
levels owing to a decreased Apo (a) production and, finally, decreases modestly triglyceride (TRG)
levels due to increased lipolysis and increased receptor-mediated catabolism of TRG-rich particles.
Interestingly, anacetrapib may be associated with a beneficial effect on carbohydrate homeostasis.
Furthermore, the Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
(REVEAL) trial showed that anacetrapib administration on top of statin treatment significantly
reduces cardiovascular events in patients with atherosclerotic vascular disease without any significant
increase of adverse events despite its long half-life. Thus, anacetrapib could be useful for the effective
management of dyslipidemias in high-risk patients that do not attain their LDL cholesterol target or
are statin intolerable, while its role in patients with increased Lp(a) levels remains to be established.
Keywords: anacetrapib; cholesteryl ester transfer protein; cardiovascular disease; apolipoprotein; diabetes
1. Introduction
Cholesteryl ester transfer protein (CETP) is a glycoprotein synthesized mainly in the liver, which
plays a prominent role in the bidirectional transfer of cholesterol esters and triglycerides (TRG) between
lipoproteins, that is the transfer of cholesterol esters from the cardioprotective high-density lipoprotein
(HDL) particles to the potentially atherogenic non-HDL particles (very low-density lipoprotein (VLDL)
particles, remnant lipoproteins and low-density lipoprotein (LDL) particles) [1,2]. Drugs that inhibit
CETP are able to increase HDL cholesterol and also to decrease serum LDL cholesterol levels [3].
However, the randomized placebo-controlled trials that evaluated the effects of three drugs of this
class, that is torcetrapib, dalcetrapib and evacetrapib, failed to show a beneficial cardiovascular
effect [4–7]. These trials were prematurely terminated due to either off-target toxicity (torcetrapib)
or lack of efficacy (dalcetrapib, evacetrapib) [4–8]. However, it has been recently reported that in the
Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial,
anacetrapib, a new CETP inhibitor, led to a significant decrease of cardiovascular events.
Thus, the aim of the review is to present the lipid/lipoprotein and cardiovascular effects of
anacetrapib, as well as to discuss possible future indications of the drug.
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2. Main Results of the REVEAL Trial
The REVEAL trial was a randomized placebo-controlled trial that assessed the efficacy and safety
of anacetrapib in 30,449 adults with atherosclerotic vascular disease on intensive atorvastatin treatment
(mean LDL cholesterol 61 mg/dL and mean non-HDL cholesterol 92 mg/dL) [9]. The administration
of 100 mg of anacetrapib for a mean follow-up period of 4.1 years was associated with a significant
reduction of the primary end point (first major coronary event) by 9% (rate ratio 0.91, 95% confidence
interval 0.85–0.97, p = 0.004). This risk reduction was evident even though patients treated with
anacetrapib exhibited slightly higher systolic blood pressure (SBP) and diastolic blood pressure
(DBP) values (by 0.7/0.3 mm Hg, respectively) at the final visit compared with the control group.
Treatment was well tolerated, and no significant differences between groups in the risk of death,
cancer or other serious adverse events were observed. In fact, the incidence of new-onset diabetes
mellitus among patients without diabetes mellitus at baseline was lower in the anacetrapib group as
compared to the control group (5.3% vs. 6%, rate ratio 0.89, 95% CI 0.79–1.00, p = 0.0496) [9].
2.1. Effects of Anacetrapib on Lipid and Lipoprotein Profile
Anacetrapib is an inhibitor of CETP, which can lead to impressive changes of the serum lipid
profile, as shown in Table 1, which includes the results of the REVEAL trial and two randomized trials
that evaluated the efficacy of the drug in both high-risk patients, as well as in patients with familial
hypercholesterolemia [9–11].






DEFINE Trial [10] (Patients with
Coronary Heart Disease or at Risk
for Coronary Heart Disease)
REVEAL Trial [9] (Patients
with Atherosclerotic
Vascular Disease) *
LDL cholesterol −39.7% ** −39.8% ***
−41% (direct method)
−17% ** (in a subgroup of
2000 patients)
HDL cholesterol +102.1% +138.1% +104%
Non-HDL cholesterol −36.4% −31.7% −18%
Apo B −24.8% −21% −18%
Apo AI +32.9% +44.7% +36%
Lp(a) −27.9% −36.4% −25%
TRG −5.5% −6.8% −7%
* Lipid levels at the trial midpoint. ** Measured by β quantification. *** LDL-cholesterol levels were calculated with
the use of the Friedewald equation: LDL cholesterol = total cholesterol − (HDL cholesterol + [triglycerides ÷ 5]).
If the triglyceride level was more than 400 mg per deciliter, LDL-cholesterol was measured by means of
preparative ultracentrifugation separation. REALIZE: Randomized Evaluation of Anacetrapib Lipid-Modifying
Therapy in Patients with Heterozygous Familial Hypercholesterolemia, DEFINE: Determining the EFficacy and
Tolerability of CETP INhibition with AnacEtrapib, REVEAL: Randomized EValuation of the Effects of Anacetrapib
Through Lipid-modification, LDL: low-density lipoprotein, HDL: high-density lipoprotein, Apo: apolipoprotein,
Lp(a): lipoprotein (a), TRG: triglycerides.
Beyond the prominent increase of HDL cholesterol, a marked decrease of LDL cholesterol was
observed in these trials. Even though the underlying mechanisms of this increase in LDL cholesterol
are not clear, kinetic data of lipid metabolism during anacetrapib administration in humans points to
the following potential mechanisms (Figure 1) [12–15]:
(1) Increased catabolism of LDL particles due to anacetrapib-associated compositional changes
of LDL particles, such as increased TRG content and particle size, leading to increased LDL particles’
affinity to the LDL receptors [15].
(2) Decreased proprotein convertase subtilisin/kexin type 9 (PCSK9) levels (a CETP-independent
mechanism) leading to decreased LDL receptors’ degradation and, therefore, increased LDL receptors’
activity and LDL particles’ catabolism [14,16].
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(3) Decreased drug-associated cellular cholesterol concentration in the liver, due to increased
cholesterol efflux, which results in the activation of sterol regulatory element-binding protein 2
(SREBP-2) leading to increased synthesis of LDL receptors [15].
(4) Reduced expression of the inducible degrader of the LDL receptors (IDOL) due to decreased
hepatic oxysterols resulting in a reduced activation of liver X receptors (LRX). This reduced IDOL
expression is associated with increased LDL receptors’ activity and subsequently with increased
catabolism of LDL particles [15].
(5) Reduced transfer of cholesterol esters from HDL to LDL is also associated with a reduction
of LDL cholesterol, though this mechanism cannot explain the observed marked reduction of
apolipoprotein (Apo) B levels that reflects a reduction in the concentration of LDL particles [12,15].
Figure 1. Potential mechanisms of anacetrapib-mediated reduction of low-density lipoprotein (LDL)
cholesterol. HDL: high-density lipoprotein, LDL: low-density lipoprotein, CETP: cholesteryl ester
transfer protein, TRG: triglycerides, SREBP: sterol regulatory element binding protein, IDOL: inducible
degrader of the low-density lipoprotein receptor, PCSK9: proprotein convertase subtilisin/kexin type 9.
Thus, many mechanisms may explain the LDL cholesterol-lowering efficacy of anacetrapib.
LDL cholesterol is an established cardiovascular risk factor and represents the main target
of hypolipidemic therapy [17,18]. Furthermore, many of the above mechanisms explain the
anacetrapib-associated lowering of Apo B levels (Table 1). In this context, the findings of the
REVEAL trial were in accordance with the results of the Cholesterol Treatment Trialists Collaboration
meta-analysis (n = 170,000 participants) [19], which showed that a reduction of non-HDL cholesterol
(which represents the Apo B-containing particles) by 17 mg/dL is expected to reduce the rate of major
coronary events by 10%. In fact, recent Mendelian randomization studies have shown that Apo B is a
better than LDL cholesterol predictor of an increased cardiovascular risk in patients with gene variants
that reflect combined CETP inhibitor and statin treatment [20]. Therefore, it has been proposed that
the anacetrapib-mediated decrease of Apo B is the main mechanism of cardiovascular risk reduction
in patients taking a statin [20].
A decrease of lipoprotein a (Lp(a)) levels was repeatedly observed after anacetrapib and other
CETP inhibitors’ administration (Table 1) [9–11]. Interestingly, a recently published study clearly
showed that the anacetrapib-mediated reduction of Lp(a) levels (by 34.1%) is due to a reduction of
the Apo (a) production rate (by 41%) and not due to changes of Apo (a) fractional catabolic rate [21].
Lp(a) is an established cardiovascular risk factor [22]; thus, the anacetrapib-mediated decrease of its
serum concentration may have played a significant role in the positive results of the REVEAL trial.
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Additionally, a small decrease of serum TRG levels is also observed with anacetrapib [9–11]
mainly due to increased catabolism of TRG-rich VLDL particles (Figure 2). The underlying
mechanisms include:
(1) Increased lipolysis of the large TRG-rich VLDL particles through lipoprotein lipase
(even without increased lipolytic activity) [23].
(2) Other compositional changes in VLDL particles, such as increased Apo E and reduced Apo
CIII content, which can increase lipoprotein lipase activity and the hepatic receptor-mediated clearance
of remnant particles [12,23].
(3) Increased hepatic uptake of the large triglyceride-rich (depleted of cholesterol) VLDL
particles [16,23].
(4) CETP-independent decreased PCSK9 levels leading to increased LDL receptors’ activity and
catabolism of VLDL particles and their remnants [16].
Figure 2. Potential mechanisms of the anacetrapib-mediated reduction of triglycerides (TRG).
PCSK9: proprotein convertase subtilisin/kexin type 9, CETP: cholesteryl ester transfer protein,
Apo: apolipoprotein, LPL: lipoprotein lipase, VLDL: very low-density lipoprotein.
Finally, a number of trials has delineated the anacetrapib-mediated changes of HDL particles,
which include a marked increase of HDL cholesterol, an increase of Apo AI levels (due to its decreased
catabolism) and a lesser increase of Apo AII levels, as well as an increase of large cholesterol-rich
alpha 2 HDL particles (HDL2 particles) and pre-beta HDL particles, which can lead to an increased
ATP-binding cassette transporter (ABCA1)-mediated cholesterol efflux (Figure 3) [24].
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Figure 3. Potential mechanisms of anacetrapib-mediated changes of high-density lipoprotein (HDL)
metabolism. CETP: cholesteryl ester transfer protein, Apo: apolipoprotein, TRG: triglycerides,
ABCA1: ATP-binding cassette transporter ABCA1 (member 1 of human transporter sub-family ABCA).
2.2. Other Effects of Anacetrapib
In contrast with the other drugs of this class, anacetrapib does not seem to exhibit significant
‘’on-target” adverse effects, such as dysfunctional HDL particles or changes in apolipoproteins
that promote atherogenesis, or ‘’off target” effects, such as a significant increase of blood
pressure or C-reactive protein levels (which is an inflammatory marker) [8,25]; these adverse
effects have been implicated in the negative or neutral cardiovascular effects of other CETP
inhibitors. However, in the REVEAL trial, slightly higher SBP and DBP values (by 0.7/0.3 mm Hg,
respectively) were observed at the final visit in anacetrapib-treated patients compared with the control
group. Alternatively, any on-target or off-target detrimental effects of anacetrapib may have been
counterbalanced by the marked decrease of Apo B-containing atherogenic lipoproteins, such as LDL,
but also Lp(a) [9].
Mendelian randomization trials have shown that hypolipidemic drugs that reduce LDL receptors’
activity are associated with a detrimental effect on carbohydrate homeostasis [26–29], which has
received much attention taking into account the wide use of these hypolipidemic drugs. The beneficial
effect of CETP inhibitors on glucose homeostasis, as shown in the REVEAL trial and previous studies [9,30],
can possibly counteract the dysglycemic effect of other hypolipidemic drugs. Thus, anacetrapib could
be a promising therapeutic strategy as an add-on therapy to current hypolipidemic treatment especially
in high-risk patients with disorders of carbohydrate metabolism.
It should be mentioned that anacetrapib has a long half-life, which is associated with advantages
concerning the patients’ compliance to therapy, but may be a disadvantage concerning side effects that
can be observed after long-term treatment [31].
3. Possible Future Indications of Anacetrapib
Based on the current knowledge regarding its effects on lipidemic profile and cardiovascular risk,
anacetrapib could be useful for the treatment of:
(1) High-risk patients who do not attain their LDL cholesterol target despite optimal hypolipidemic
treatment. Currently, these patients could take a PCSK9 inhibitor [32,33], but anacetrapib could be
alternatively used taking into account that it is associated with a reduction of cardiovascular events, is
given orally once per day (in contrast with the parenteral administration of current PCSK9 inhibitors)
and probably will have a much lower cost.
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(2) Patients with familial hypercholesterolemia with difficulty achieving their LDL cholesterol
target despite optimal hypolipidemic treatment, in whom anacetrapib is associated with a significant
improvement of lipid and lipoprotein profile (Table 1).
(3) Patients with statin intolerance, in whom the use of the expensive and parenteral PCSK9
inhibitors is not easily accepted. This possible indication of anacetrapib could be the most important
in the future since non-statin treatment with a potent CETP inhibitor (possibly in combination with
ezetimibe) could be associated with large concordant absolute reductions of both LDL cholesterol and
Apo B and, therefore, of cardiovascular risk [20].
(4) Patients with increased serum Lp(a) levels, although more data are needed in this population.
It is worth mentioning that two new CETP inhibitors that induce significant beneficial changes
in lipidemic profile (including a reduction of Apo B-containing lipoproteins) are under investigation
[Obicetrapib (AMG-899, TA-8995) and K-312] [34,35]. The results of the relative studies will show
whether there is a class effect of CETP inhibitors on cardiovascular events and will help to delineate
the implicated mechanisms.
4. Conclusions
Anacetrapib is associated with significant improvement of lipid and lipoprotein profile and
a significant reduction of cardiovascular events in high-risk patients on optimal statin treatment.
These data may suggest that anacetrapib could be a useful therapeutic option for the effective
hypolipidemic treatment of high-risk patients especially if the results of ongoing trials with other
CETP inhibitors confirm the positive cardiovascular effects of this drug class.
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Abstract: Adipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local
roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was
negatively correlated with blood pressure in obese patients, while vaspin levels were decreased in
endothelial dysfunction. The aim of the present study was to determine rosuvastatin modulation
effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. A total number
of seventy patients with acute coronary syndrome previously and currently treated with rosuvastatin
was compared to 40 patients with IHD not treated by rosuvastatin as a control. Vaspin serum
levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the
patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Additionally, in the
rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to
NSTEMI p < 0.01. Conclusion: Rosuvastatin significantly increases vaspin serum levels in acute
coronary syndrome.
Keywords: vaspin; acute coronary syndrome; NSTEMI; STEMI
1. Introduction
Acute coronary syndrome (ACS) is a cluster of pathological conditions due to a reduction in
coronary blood flow caused by coronary thrombosis and/or atherosclerosis, leading to myocardial
ischemia and necrosis [1]. Acute coronary syndrome includes ST-elevation myocardial infarction
(STEMI) 30%, non-ST elevation myocardial infarction (NSTEMI) 25%, and unstable angina 38%;
these are classified according to electrocardiographic changes in ST-segment [2]. Acute coronary
syndrome should be differentiated from stable angina (crescendo angina); in addition, new onset
angina should be regarded as part of ACS [3]. Acute myocardial infarction (MI) is known as myocardial
cell death (necrosis) because of prolonged myocardial ischemia, STEMI occurs when the coronary artery
thrombus is initiated rapidly at coronary vascular wall injury, which can be triggered by many factors,
including hypertension, cigarette smoking and dyslipidemia [4]. Unstable angina/non-ST-elevation
MI patients usually have numerous vulnerable plaques at risk of disruption and rupture, so platelet
aggregation in acute coronary syndromes (ACS) leads to unstable plaque [5]. The damage to the
full thickness of the heart muscle is an indicator of increased damage percentage, while the partial
thickness of the heart muscle damage is called NSTEMI [6].
ACS is associated with inflammatory and non-inflammatory risk factors; high blood levels of
C-reactive protein (CRP) may be linked with risk of coronary artery disease and having a heart
attack [7]. In healthy people without hyperlipidemia but with increased CRP levels, the statin drugs
rosuvastatin significantly reduced the acute cardiovascular events [8,9].
Visceral Adipose Tissue-Derived Serpin (vaspin) is a novel adipokine that is expressed mainly in
visceral white adipose tissue [10]. The up-regulation of vaspin synthesis may signify a response to the
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antagonizing action of fat-derived proteases that antagonize the insulin action; therefore, up-regulation
of vaspin expression may be regarded as a defense mechanism against insulin resistance [11].
Additionally, vaspin was negatively correlated with blood pressure in obese patients, while vaspin
levels were decreased in patients with impaired endothelial function [12]. Inflammation was thought to
be one of the major causes of early atherosclerosis and its complications [13]. Recently, a study predicted
that adipokines including vaspin have a local role in preventing the progression of atherosclerotic
growth of [14].
Class I obesity is defined by the WHO as moderate obesity where body mass index (BMI) range is
30–35 kg/m2; obesity is positively correlated with the incidence of the acute coronary syndrome and
vaspin serum levels [15].
Statins are the most broadly used lipid-lowering agents in patients with dyslipidemia, they reduce
the cardio-metabolic risk factors, morbidity and mortality of cardiovascular diseases independent of
their lipid-lowering effect. These effects were observed along with an augmentation in vaspin serum
levels [16].
Rosuvastatin is a HMG-CoA reductase inhibitor indicated for dyslipidemia and approved in
2010 by the FDA for primary prevention of ACS due to a reduction in the cardiovascular risk factors
regardless of lipid profile levels [17].
Therefore, the aim of the present study was to determine the effect of rosuvastatin on vaspin
serum levels in obese patients with acute coronary syndrome.
2. Patient and Methods
In this cohort study, a total number of seventy patients (50 males, 20 females) previously
and currently treated with rosuvastatin—25 patients with unstable angina pectoris (12 male and
13 female), 25 patients with STEMI (22 male and 3 female) and 20 patients with NSTEMI (16 male
and 4 female)—were enrolled in the study and compared to 40 patients with IHD not treated by
rosuvastatin, as a control. Each patient was clinically examined by the consultant, and the diagnosis
was achieved by electrocardiograph ECG, cardiac enzymes, and cardiac Troponin (cTnI). The inclusion
criteria were: unstable angina pectoris, STEMI and NSTEMI patients with recent acute myocardial
infarction admitted to the coronary care unit (CCU). The exclusion criteria were patients with valvular
heart diseases, malignant diseases, acute infection, inflammatory disorders, blood disorders, advanced
renal disease, liver disease, smoking and diabetes mellitus. All enrolled patients and controlled subjects
gave written informed approval before their participation. The procedures were prepared according to
the Declaration of Helsinki. This study was approved by the Clinical Research, Ethical Committee,
College of Medicine, Al-Mustansiriyiah University, Baghdad-Iraq.
3. Sample Collections and Anthropometric Profiles
After the interview, medical history, current drug pharmacotherapy and anthropometric measures
were examined. Body mass index was estimated as kg/m2, waist and hip circumferences were
recorded, and the waist-hip ratio was calculated. Waist-hip ratio was determined by dividing the
waist (cm) by the hip (cm), using a cutoff level <0.85 in females and <0.9 in males [18]. Ten milliliters
of venous blood was withdrawn at 9 a.m. after overnight fasting, into a plain tube 5 mL (for routine
investigations) and into an EDTA tube 5 mL for vaspin and (cTnI) estimations.
Vaspin and cTnI serum levels were determined by ELISA KIT method (vaspin inhibitor) in pg/mL
at 450 nm and human troponin-I (TNNI2) in pg/mL at 450 nm, respectively.
Assessment of lipid profile: triglyceride (TG), total cholesterol (TC) and high-density lipoprotein
(HDL) were assessed by specific ELISA kits; from this profile, we can measure the following: [19]
Atherogenic index (AI) = log (TG/HDL), when TG and HDL measured in mmol/L.
LDL = (TC)-(HDL)-(TG)/5.
VLDL = TG/5.
Cardiac risk ratio (CRR) = TC/HDL.
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4. Statistical Analysis
Data analysis was done using SPSS (IBM SPSS, Stastics for Window, Version 22.00; 2014, Armonk,
NY, USA: IBM Corp.). Results are expressed as mean ± SD, number and percentage. Unpaired student
t test was used for estimation of differences between two different groups and one way ANOVA test
for estimation the differences among treated groups in terms of 95% confidence interval and t value.
Pearson correlation coefficient was used to evaluate the correlation of vaspin serum levels with other
study parameters. The results were regarded as significant when p < 0.05.
5. Results
Baseline characteristics of the present study between the study group (the rosuvastatin-treated
group) and the control group (the rosuvastatin-free group) demonstrated non-significant differences
in most of the patient variables p > 0.05 but, there were significant differences in the presentation of
hypertension and current statin therapy p < 0.0001, in addition to minor differences regarding other
pharmacotherapy p < 0.05, Table 1.
Table 1. Baseline characteristics of the present study.
Variables
Rosuvastatin Group Control Group p Value
(n = 70) (n = 40)
Age 47.87 ± 12.72 49.85 ± 11.83 0.52
Gender
M:F ratio (71.42:28.57)% (22:18) % -
BMI 31.44 ± 7.81 32.39 ± 6.77 0.59
W-H ratio
Men 1.32 ± 0.67 1.39 ± 0.77 0.71
Women 0.88 ± 0.31 0.91 ± 0.11 0.67
Hypertension 70 (100%) 20 (100%) <0.0001 **
ACS
STEMI 25 (35.71%) 8 (40%) 0.72
NSTEMI 25 (35.71%) 10 (50%) 0.24
UA 20 (28.57%) 2 (10%) 0.08
Troponin positive 67 (95.71%) 18 (90%) 0.32
Troponin negative 3 (4.28%) 2 (10%) 0.32
Dyslipidemia 64 (44.8%) 18 (90%) 0.84
Duration of IHD (years) 8.42 ± 2.28 7.44 ± 2.39 0.11
Diabetes mellitus 3 (4.28%) 2 (10%) 0.32
Pharmacotherapy
Anticoagulant 44 (62.58%) 17 (85%) 0.06
Antiplatelet 70 (100%) 18 (90%) 0.0072
ACEIs 44 (62.58%) 18 (90%) 0.02 *
Statins 70 (100%) - <0.0001 **
CCB 22 (31.42%) 12 (60%) 0.02 *
β-blockers 6 (8.57%) 5 (25%) 0.04 *
Insulin 3 (4.28%) 2 (10%) 0.32
Complications 10 (15.71%) 4 (20%) 0.53
Shock 2 (2.85%) 1 (5%) 0.63
Heart failure 5 (3.5%) 2 (10%) 0.67
Cardiac aneurysm 1 (1.42%) 1 (5%) 0.33
Death 2 (2.85%) 1 (5%) 0.33
Data presented as mean ± SD, number and %, * p < 0.05, ** p < 0.01 versus control. W-H ratio: waist-hip ratio.
Vaspin serum levels were higher in the study group compared to the control group p < 0.01,
whereas there were non-significant differences in serum cardiac troponin-I serum level, diastolic blood
pressure and blood glucose p > 0.05. Moreover, the rosuvastatin-treated group revealed significant
differences among other biochemical variables compared to the control group (the rosuvastatin-free
group), particularly on high-sensitivity CRP, Table 2.
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Serum cTn-I pg/mL) 74.54 ± 13.32 77.64 ± 12.22 −0.98 3.33–9.53 0.33
Serum vaspin(pg/mL) 603.83 ± 18.13 542.75 ± 38.95 6.8 79.72–42.33 <0.0001 **
TC (mg/dL) 199.28 ± 20.49 266.43 ± 16.59 −15.1 −134.29 <0.0001 **
TG (mg/dL) 166.83 ± 17.34 254.73 ± 22.82 −15.95 −175.78 <0.0001 **
LDL (mg/dL) 118.80 ± 8.75 164.71 ± 13.59 −14.28 −81.81 <0.0001 **
HDL(mg/dL) 47.11 ± 9.86 50.76 ± 7.34 −1.8 0.43–7.73 0.078
VLDL (mg/dL) 33.36 ± 5.83 50.94 ± 6.42 −11.01 −35.15 <0.0001 **
AI 0.189 ± 0.012 0.341 ± 0.021 −30.95 −0.3 <0.0001 **
CRR 4.23 ± 1.44 5.24 ± 1.98 −2.12 −2.01 0.04 *
SBP (mmHg) 166.54 ± 21.54 155.87 ± 19.63 2.09 21.02–0.31 0.043 *
DBP (mmHg) 92.23 ± 22.69 87.67 ± 13.75 1.11 12.78–3.66 0.27
FBG (mg/dL) 101.65 ± 11.93 97.87 ± 8.97 1.53 8.75–1.19 0.132
PPG(mg/dL) 128.64 ± 11.83 132.64 ± 12.74 −1.25 2.50–10.50 0.21
Hs-CRP (mg/L) 2.95 ± 0.45 4.65 ± 1.84 −4.09 −3.39 0.0006 **
Data presented as mean ± SD, * p < 0.05, ** p < 0.01 versus control; cTn-I: cardiac troponin-I; TG: triglyceride;
TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; VLDL: very low density
lipoprotein; AI: atherogenic index; CRR: cardiac risk ratio; SBP: systolic blood pressure; DBP: diastolic blood
pressure; FBG: fasting blood glucose; PPG: postprandial glucose; Hs-CRP: highly sensitive CRP.
Regarding the intra-group and inter-group differences, unstable angina versus control showed
a significant difference in vaspin and cardiac troponin-I sera levels in addition to the other
cardio-metabolic variables, except in cardiac risk ratio (CCR); in the same manner, these differences
were found between STEMI and NSTEMI versus control. In the rosuvastatin-treated group, patients
with STEMI showed higher vaspin serum levels and lower atherogenic index compared to NSTEMI
Table 3.
Table 3. Intra and inter-groups difference in cardio-metabolic variables.
Cardio-Metabolic Variables STEMI (n = 25) NSTEMI (n = 25) Unstable Angina
(n = 20) Control (n = 40)
Serum cTn-I (pg/mL) 74.12 ± 12.45 72.65 ± 22.49 54.45 ± 23.53 ** 77.64 ± 12.22
Serum vaspin (pg/mL) 611.32 ± 33.64 ** 588.67 ± 22.29 ** 586.87 ± 33.72 ** 542.75 ± 38.95
TC (mg/dL) 197.28 ± 21.77 ** 192.99 ± 19.64 ** 193.64 ± 20.65 ** 266.43 ± 16.59
TG (mg/dL) 160.83 ± 19.42 ** 167.54 ± 18.74 ** 166.83 ± 16.84 ** 254.73 ± 22.82
LDL (mg/dL) 117.78 ± 8.75 ** 113.85 ± 9.98 ** 112.63 ± 13.83 ** 164.71 ± 13.59
HDL (mg/dL) 47.33 ± 9.77 45.63 ± 8.99 45.55 ± 8.33 * 31.76 ± 7.34
VLDL (mg/dL) 32.16 ± 5.88 ** 33.50 ± 4.34 ** 33.57 ± 4.22 ** 50.94 ± 6.42
AI 0.171 ± 0.011 ** 0.205 ± 0.014 ** 0.204 ± 0.012 ** 0.341 ± 0.021
CRR 4.16 ± 1.65 4.22 ± 1.99 4.25 ± 1.86 5.24 ± 1.98
SBP (mmHg) 162.66 ± 20.33 165.62 ± 19.82 164.76 ± 18.93 155.87 ± 19.63
DBP (mmHg) 91.20 ± 20.39 93.53 ± 20.37 93.77 ± 20.53 87.67 ± 13.75
Pulse pressure (mmHg) 71.46 ± 11.76 72.09 ± 10.74 70.99 ± 11.55 68.20 ± 9.33
FBG (mg/dL) 101.44 ± 10.98 100.54 ± 10.71 104.61 ± 9.88 97.87 ± 8.97
PPG (mg/dL) 129.60 ± 10.82 127.55 ± 9.76 126.83 ± 9.38 132.64 ± 12.74
Hs-CRP (mg/L) 2.93 ± 0.44 ** 2.89 ± 0.45 ** 1.44 ± 0.11 ** 4.65 ± 1.84
Data presented as mean ± SD, * p < 0.05, ** p < 0.01 versus control, p < 0.01 (STEMI versus NSTEMI); cTn-I: cardiac
troponin-I; TG: triglyceride; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein;
VLDL: very low density lipoprotein; AI: atherogenic index; CRR: cardiac risk ratio; SBP: systolic blood pressure;
DBP: diastolic blood pressure; FBG: fasting blood glucose; PPG: postprandial glucose; Hs-CRP: highly sensitive CRP.
Therefore, vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary
syndrome compared to the patients with acute coronary syndrome not treated with rosuvastatin.
Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum
levels compared to NSTEMI.
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Indeed, there is a non-significant negative correlation between vaspin serum levels and Hs-CRP


























Figure 1. Negative correlation between vaspin serum levels and Hs-CRP in rosuvastatin-treated ACS.
Meanwhile, in control patients (rosuvastatin free), there was a significant negative correlation


























Figure 2. Negative correlation between vaspin serum levels and Hs-CRP in rosuvastatin-free
ACS patients.
Vaspin serum levels were positively correlated with cTn-I (p < 0.001) and HDL (p = 0.0003),
but negatively correlated with total cholesterol (p = 0.007), triglyceride (p = 0.04) and atherogenic
index (p = 0.04) in patients with STEMI. Meanwhile, in patients with NSTEMI, vaspin serum levels
were mainly correlated with cTn-I, total cholesterol and HDL p < 0.01; while in patients with unstable
angina, vaspin serum levels were only correlated with total cholesterol and HDL p < 0.01. In the control
patients (rosuvastatin-free patients), vaspin serum levels were correlated with cardio-metabolic risk
profile p < 0.05, see Table 4.
Regarding the sensitivity and specificity of vaspin serum levels in patients with ACS, high vaspin
serum levels( more than 550 pg/mL) were found in 65 patients (treated group) compared to 6 patients
(control group) p < 0.05 (positive predictive value 0.915 with 95% CI 0.818−0.965), whereas low vaspin
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serum levels (less than 550 pg/mL) were found in 5 patients (treated group) compared to 34 patients
(control group) p < 0.05 (negative predictive value 0.871 with 95% CI 0.717−0.951), see Figure 3.
Table 4. Pearson correlation for vaspin serum levels with the cardio-metabolic risk factors in patients
with acute coronary syndrome.
Variables
STEMI (n = 25) NSTEMI (n = 25) UA (n = 20) Control (n = 40)
r p r p r p r p
Serum cTn-I (pg/mL) 0.87 0.001 * 0.77 0.0001 * 0.44 NS 0.94 0.0001 *
TC (mg/dL) −0.52 0.007 * −0.67 0.0002 * −0.67 0.001 * −0.56 0.007 *
TG (mg/dL) −0.41 0.04 ! −0.32 NS −0.36 NS −0.75 0.001 *
LDL (mg/dL) −0.33 NS −0.32 NS 0.38 NS −0.63 0.0002 *
HDL (mg/dL) 0.66 0.0003 * 0.69 0.0002 * 0.71 0.0004 * 0.51 0.008 *
VLDL (mg/dL) −0.31 NS −0.34 NS −0.38 NS −0.42 0.006 *
AI −0.41 0.04 ! −0.35 NS −0.41 NS −0.51 0.0007 *
CRR −0.34 NS −0.31 NS −0.37 NS −0.41 0.008 *
SBP (mmHg) −0.33 NS −0.36 NS −0.32 NS −0.42 0.006 *
DBP (mmHg) −0.37 NS −0.30 NS −0.22 NS −0.41 0.008 *
FBG (mg/dL) −0.28 NS −0.32 NS −0.30 NS −0.33 0.03 !
Pearson correlation (r); * p < 0.01; ! p < 0.05; NS: non-significant; UA: unstable angina; cTn-I: cardiac troponin-I;
TG: triglyceride; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; VLDL: very
low density lipoprotein; AI: atherogenic index; CRR: cardiac risk ratio; SBP: systolic blood pressure; DBP: diastolic
blood pressure; FBG: fasting blood glucose.
p < 0.05 
p < 0.0
Figure 3. Sensitivity and specificity of vaspin serum levels in patients with acute coronary syndrome
treated with or without rosuvastatin.
Thus, vaspin serum levels were high in patients with ACS on rosuvastatin therapy (595.62 ± 23.65)
compared to patients with ACS not on rosuvastatin therapy (542.75 ± 38.95), see Figure 4.
Figure 4. Vaspin serum levels in patients with ACS regarding rosuvastatin therapy.
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6. Discussion
Vaspin was initially recognized as an adipokine, mainly secreted from visceral adipose tissue
in Otsuka Long-Evans Tokushima Fatty (OLETF), which is an animal model of obesity and diabetes
mellitus [20]. Higher vaspin mRNA expression is correlated with type 2 diabetes mellitus, obesity and
insulin resistance; this increment in vaspin serum levels leads to improvements in glucose metabolism
and insulin sensitivity in visceral adipose tissue, but the main molecular mechanism of vaspin is
unidentified [21]. Moreover, vaspin plays an important role in the modulation of coronary vessel
homeostasis, since vaspin has a local effect on coronary vascular endothelium [22].
The present study demonstrated higher vaspin serum levels in both the study and control groups;
given that the patients in both groups were obese class I type (BMI > 30 kg/m2), this corresponds
to the study by Cho et al., which revealed a significant correlation between vaspin levels and
BMI, since vaspin concentrations were increased and correlated with elevated total body fat
percentage. For this reason, vaspin concentrations can be regarded as an indicator of obesity [23].
The waist-hip ratio of enrolled patients in the present study was high in both enrolled men and women.
This ratio was associated with a high vaspin concentration; this finding correlates with that of the
Amouzad et al., 2014 study, which revealed a positive link between elevated waist-hip ratio and serum
vaspin concentrations in obesity and metabolic syndromes [24]. Contradictory studies have reported
low vaspin serum concentration in obesity compared to normal healthy volunteers [25], which does
not correspond with the findings of the present study.
Serum vaspin concentrations of our work were relatively low in patients with ACS, which is
consistent with the study by Kobat et al., which demonstrated low vaspin serum levels in patients
with ACS and coronary atherosclerosis [26].
The current study also revealed a higher vaspin serum concentration in patients with ACS
previously and currently treated with rosuvastatin compared with patients with ACS not previously
and currently treated by statins; this result is supported by the 2011 study by Kadoglou et al.,
which revealed that the pleiotropic effects of statin may increase vaspin serum levels in patients
with ischemic heart disease [27].
Moreover, serum vaspin concentrations may be equal in unstable angina and NSTEMI, but there
was a significant difference in serum vaspin concentrations between NSTEMI and STEMI. When it is
higher in STEMI, this may be due to rosuvastatin effects, and all of the enrolled patients were obese
since vaspin serum levels are higher in obesity and are provoked by statins therapy, because statins
produced more significant anti-inflammatory effects in STEMI than NSTEMI [28].
Rosuvastatin has potent immuno-modulatory and anti-inflammatory effects due to its inhibition
of pro-inflammatory mediators, including tumor necrosis factor (TNF-α), interleukin-6 and C-reactive
protein [29], which corresponds with our findings, which revealed a decline in highly sensitive
C-reactive protein (hs-CRP) in rosuvastatin-treated patients compared to non-treated patients with
ACS. This may explain the decremental effects of rosuvastatin on morbidity of cardio-metabolic risk
profile independent of/from lipid-lowering property, which is called the pleiotropic effect [30].
Consequently, the 2011 study of Kodaglou et al. pointed out that inflammatory pathways are the
link between obesity and coronary heart diseases, vaspin serum levels showed an inverse association
with acute cardiac ischemic events, so low vaspin concentrations were correlated with ACS severity,
which is suggestive of the cardio-protective effects of vaspin [31].
Vaspin plays an important role in the prevention of vascular and coronary endothelial injuries
and inflammation through down-regulation of intracellular adhesion molecules induced by TNF-α,
inhibition of reactive oxygen species, inhibition of platelet-derived growth factor, and suppression of
free radical-dependent p38/HSP27 activation [32,33]. Thus, rosuvastatin, like other statins, leads to
direct or indirect anti-inflammatory effect via increment in vaspin serum levels that ameliorates acute
inflammatory changes in ACS [34], as presented in the present study through elevation of vaspin
serum levels and decrement in Hs-CRP.
15
Diseases 2018, 6, 9
Additionally, vaspin shows a diurnal variation, high at morning and fasting, and low at the
postprandial period; additionally, high vaspin serum levels were reported to be higher in the Asian
population [35], these variations may explain high vaspin serum levels in the current study, because
all of the selected patients were Asians, and blood sampling was done in the morning to exclude
these variations.
Indeed, hs-CRP serum level is an inflammatory marker that increased within two days following
ACS, but not in unstable angina; this increment continued for three months subsequent to myocardial
infarction [36]. Rosuvastatin significantly reduces Hs-CRP serum levels through its anti-inflammatory
properties, as shown in the present study.
Finally, the present study illustrated the inverse correlation of vaspin serum levels with most
cardio-metabolic risk profiles in patients with acute coronary syndromes not treated with rosuvastatin,
compared to rosuvastatin-treated patients. These findings are in agreement with many studies showing
that vaspin levels were found to have an inverse link with the cardio-metabolic events, signifying the
protective effect of vaspin in the prevention of coronary atherosclerosis and amelioration of cardiac
risk factors [37,38]. Unfortunately, this study did not measure insulin levels; additionally, gender and
race differences were not evaluated. These limitations may be a project for future research.
7. Conclusions
Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome.
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Abstract: Each year, a large number of patients undergo coronary artery bypass grafting surgery
(CABG) worldwide. Accumulating evidence suggests that the preoperative administration of statins
might be useful in preventing adverse events after CABG. In the present review, we discuss the role of
statins in the perioperative management of patients undergoing CABG. Preoperative administration
of statins in these patients substantially reduces the risk of postoperative atrial fibrillation and shortens
hospital and intensive care unit (ICU) stay. Atorvastatin appears to be more effective, particularly
when administered at high doses. Given these benefits and the safety of statins, their administration
should be considered in patients undergoing CABG, even though the statins do not appear to affect
the incidence of cardiovascular events and overall mortality perioperatively.
Keywords: statins; coronary artery bypass grafting; pleiotropic actions; atrial fibrillation; stroke;
acute kidney injury
1. Introduction
Each year, a large number of patients undergo coronary artery bypass grafting surgery (CABG)
worldwide [1]. Despite improved surgical techniques, the advances in technology used in the operating
room (new cardiopulmonary bypass machines and cannulas, more precise sensors and monitoring),
improved cardiac anesthesiologic management, and the more experience gathered by surgeons over
the years, CABG is still associated with a considerable risk for adverse events, including death [1].
As a result, lowering postoperative morbidity is not only an intraoperative challenge, but also depends
on preoperative management. In this context, it is worthy to look back over the publications from
years 2000–2007, accumulating evidence that suggests that the preoperative administration of statins
might be useful in preventing adverse events after CABG [2–4].
In the present review, we discuss the role of statins in the perioperative management of patients
undergoing CABG.
2. Effects of Statins on Atrial Fibrillation after CABG
In the Atorvastatin for reduction of myocardial Dysrhythmia after cardiac surgery (ARMYDA-3
study), a randomized, placebo-controlled study (n = 200), treatment with atorvastatin (40 mg/day for
seven days) before cardiac surgery (not only isolated CABG) reduced the incidence of postoperative
atrial fibrillation by 61% [5]. In a meta-analysis of 3 randomized controlled trials (RCTs) and 10
observational studies (n = 17,643), statin treatment before CABG reduced the risk for any postoperative
atrial fibrillation by 36% and for new-onset atrial fibrillation by 34% [6]. In a more recent meta-analysis
of 12 RCTs in 2980 patients, statin treatment before CABG reduced the incidence of postoperative
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atrial fibrillation by 58% [7]. Notably, atorvastatin reduced the risk by 65%, whereas rosuvastatin was
not protective [7]. Rosuvastatin also did not reduce the incidence of post-CABG atrial fibrillation in
the Statin Therapy In Cardiac Surgery (STICS) trial, a large RCT (n = 1922) [8]. The reason for the
different outcome between atorvastatin and rosuvastatin is mainly unknown. In addition, it should be
mentioned that only two small studies evaluated the effects of the administration of pravastatin and
simvastatin on the risk of atrial fibrillation in patients undergoing CABG (n = 43 and 44, respectively) [7].
Even though these studies showed no effect of these statins on the incidence of atrial fibrillation,
more data are clearly needed to clarify whether these statins might also prevent this complication.
In addition, there are no studies that evaluated the effects of other statins (fluvastatin, pitavastatin) on
the incidence of atrial fibrillation in patients undergoing CABG [7].
Regarding the association between statin dose and the risk of atrial fibrillation, an early
retrospective study showed that a high-dose statin treatment reduces the risk for atrial fibrillation after
CABG more than an intermediate-dose treatment, whereas a low-dose treatment has no protective
effect [9]. In contrast, in a duration- and dose-response meta-analysis of eight RCTs (n = 774), there was
no association between statin dose and risk reduction (p = 0.47) [10]. Nevertheless, it should be
emphasized that both the lipid-lowering and the pleiotropic effects of statins (e.g., anti-inflammatory,
antioxidant, and antithrombotic actions) as well as the reduction in cardiovascular risk with these
agents are clearly dose-dependent [11]. Therefore, it is possible that this meta-analysis included a
small number of patients and did not have the statistical power to show an association between
statin dose and the incidence of atrial fibrillation. On the other hand, in the former meta-analysis,
a longer duration of preoperative statin treatment was associated with a greater reduction in the risk
of postoperative atrial fibrillation (3% reduction per day of statin treatment, p = 0.008) [10].
The physiological mechanism(s) underpinning the preventive effect of statin against postoperative
atrial fibrillation are still unknown. The pleiotropic effects of statins, including anti-inflammatory,
antioxidant, and antithrombotic actions as well as inhibition of neurohormonal activation, appear to
play a role [11,12].
3. Effects of Statins on Hospital and Intensive Care Unit (ICU) Stay after CABG
Several studies showed that preoperative statin therapy shortens hospital stay by approximately
0.5 days [7,10,13–15]. Preoperative statin therapy also reduces postoperative ICU stay, but this
reduction is more modest (by 3–4 h) [10,13]. It is possible that the reduction in the incidence
of atrial fibrillation and its associated complications, including embolic stroke and hemodynamic
instability, contribute to the shortening of hospitalization in patients who receive statins prior to
CABG [7,10,13–15].
4. Effects of Statins on Renal Failure, Myocardial Infarction, Stroke, and Mortality after CABG
Postoperative acute kidney injury is a frequent complication in patients undergoing
CABG [12,13,16–18]. Observational studies suggested that pretreatment with statins reduces the
risk of postoperative renal failure and the need for hemodialysis in this population [19–21]. In contrast,
an RCT showed that atorvastatin does not affect the incidence of acute kidney injury after CABG [22]
whereas in the STICS trial, the rate of postoperative acute kidney injury was higher in patients who
received rosuvastatin prior to CABG compared with patients who received a placebo [8]. Several
systematic reviews and meta-analyses concluded that treatment with statins before CABG does not
affect the risk of acute kidney injury [12,13,18].
Preoperative treatment with statins does not appear to reduce the risk for postoperative
myocardial infarction (MI) [13,17]. However, a meta-analysis of eight studies (n = 8676) showed
that patients who receive a loading dose of statin prior to CABG have a lower risk for non-fatal and
fatal MI as well as a lower risk for graft restenosis and repeat CABG than patients who receive a
regular dose [23]. In a prospective observational study, patients who received high-intensity statin
treatment (i.e., expected to reduce low-density lipoprotein cholesterol (LDL-C) levels by >45%) had a
20
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lower risk for cardiovascular events than patients who received moderate-intensity statin treatment
(i.e., expected to reduce LDL-C levels by <45%) [24].
The incidence of postoperative ischemic stroke also does not appear to be affected by the
administration of statins before CABG [13,16,17]. However, a single-center study suggested that
the combination of statins with beta blockers reduces the risk for ischemic stroke after CABG [25].
Clearly, more studies are needed to confirm this promising finding.
An early retrospective cohort study suggested that pretreatment with statins is associated with
reduced postoperative 30-day all-cause mortality after CABG [17]. However, several more recent RCTs
and meta-analyses did not identify any survival benefit with statin treatment in these patients [13,15,16].
5. Conclusions
The preoperative administration of statins in patients undergoing CABG substantially reduces
the risk of postoperative atrial fibrillation and shortens hospital and ICU stay. Atorvastatin appears to
be more effective, particularly when administered at high doses. Given these benefits and the safety
of statins, their administration should be considered in patients undergoing CABG, even though
the statins do not appear to affect the incidence of cardiovascular events and overall mortality
perioperatively. More studies are needed to clarify the mechanisms underpinning these beneficial
effects of statins and to define the optimal compound, dose, and duration of treatment.
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Abstract: Raised serum cholesterol concentration is a well-established risk factor in cardiovascular
disease. In addition, genetic load may have an indirect influence on cardiovascular risk. Plant-based
sterol-supplemented foods are recommended to help reduce the serum low-density lipoprotein
cholesterol level. The objective was to analyse the influence of different polymorphisms in
hypercholesterolemia patients following a dietary treatment with plant sterols. A randomised
double-blind cross-over controlled clinical trial was carried out in 45 people (25 women). Commercial
milk, containing 2.24 g of sterols, was ingested daily during a 3-week period, and then the same
amount of skim milk, without sterols, was consumed daily during the 3-week placebo phase. Both
phases were separated by a washout period of 2 weeks. At the beginning and end of each phase,
blood draws were performed. Genes LIPC C-514T and APOA5 C56G are Ser19Trp carriers and greatly
benefit from sterol intake in the diet. LIPC C-514T TT homozygous carriers had lower low-density
lipoprotein cholesterol (LDL-c) levels than CC homozygote and CT heterozygote carriers after the
ingestion of plant sterols (p = 0.001). These two genes also showed statistically significant changes in
total cholesterol levels (p = 0.025; p = 0.005), and no significant changes in high-density lipoprotein
(HDL) cholesterol levels (p = 0.032; p = 0.003), respectively. No statistically significant differences
were observed for other genes. Further studies are needed to establish which genotype combinations
would be the most protective against hypercholesterolemia.
Keywords: genetic; nutrigenetics; sterol; cholesterol; low-density lipoprotein cholesterol;
cardiovascular disease
1. Introduction
Human health is a result of complex interactions between genetic predisposition and the
environment in which genes manifest. It has long been recognised that individual differences in
genetic variation influence the association between dietary recommendations and health, which is yet
to be reflected in the dietary guidelines. Identifying the interplay between genes and dietary patterns
holds promise for a new era of personalised medicine, whereby the recommended diet for best health
is tailored towards how an individual’s metabolism is genetically predisposed to respond to dietary
intake [1].
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The understanding of genetic approaches in the nutritional sciences is referred to as nutrigenomics.
Nutrigenomics explores the interaction between genetic factors and dietary nutrient intake regarding
various disease phenotypes and general health [2], with the aim to provide more personalised dietary
advice [3,4].
Through the use of genome-wide association studies, genetic variations (single nucleotide
polymorphisms) have been identified as genetic factors, making it more likely to determine individual
disease predisposition [2].
Naturally occurring variants of the apolipoprotein A5 gene have been associated with increased
triglyceride levels, and have been found to confer risk for cardiovascular diseases. Some of the
MTHFR gene polymorphisms are also associated with an increased risk of congenital heart failure [5]
and cardiovascular disease [6], especially the C677T genetic polymorphism [7]. The hepatic lipase
gene (LIPC) is responsible for the hydrolysis of triglycerides [8]. Genetic studies and numerous
epidemiologic studies have identified Lp(a) as a risk factor for atherosclerotic diseases, such as
coronary heart disease and stroke [9], as it is related to low-density lipoprotein cholesterol (LDL-c) [10].
In addition, the genetic load may have an indirect influence on cardiovascular risk. ApoE plays an
essential role in the catabolism of lipoproteins [11].
Cholesterol metabolism is a well-defined responder to dietary intake, and a classic biomarker
of cardiovascular health. For this reason, circulating cholesterol levels have become essential in
shaping the nutritional recommendations of health authorities worldwide for better management
of cardiovascular disease, a leading cause of mortality and one of the most costly health problems
globally [12].
A number of cholesterol-related gene–diet interactions have been confirmed, some of which may
have clinical importance, supporting a deeper insight into the rapidly emerging field of nutrigenetics
for meaningful conclusions that may eventually lead to genetically-targeted dietary recommendations,
in the era of personalised nutrition [12].
On the other hand, nutrition and dietary treatments are important in managing cardiovascular
disease. Plant sterols have been postulated as beneficial regulatory agents for the control of the
disease [13–15]. The daily consumption of phytosterol-enriched foods is widely prescribed as a
therapeutic option to reduce LDL-c levels in plasma, and therefore reduce the risk of atherosclerotic
disease [16].
Experts from the European Food Safety Authority confirmed that blood cholesterol can be reduced
by an average of 7–10.5% if a person consumes 1.5–2.4 g of plant sterols a day. This effect is generally
observed within the first 2–3 weeks. Mid- and long-term studies, of up to 85 weeks, show that the
blood cholesterol reducing effect could be sustained throughout that period [17].
Future studies should be carried out, with the aim of learning about the increasing difference and
soundness of dietary treatment data available in concordance with individual genomic profiles.
The aim of this study was to analyse the influence of different polymorphisms in hypercholesterolemia
patients following dietary treatment with plant sterols.
2. Materials and Methods
A randomised double-blind cross-over controlled clinical trial was designed. Participants were
recruited at the San Carlos Clinical University Hospital in Madrid (SCCUHM) and the El Escorial
Hospital in Madrid. Volunteers throughout the hospital were invited to participate. Patients from
primary care and endocrinology departments were specifically invited to participate. Prior to the
trial, the participants received instructions on the purpose of the study and signed an informed
consent form.
The plant sterols were ingested using Naturcol milk (supplied by Corporación Alimentaria Peñasanta,
S.A., Asturias, Spain), available on the market throughout the whole study. Treatment and placebo
skim milk were identical in sensorial and nutrient composition.
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In this crossover study, all subjects participated in both groups, with two phases of three weeks of
each treatment, separated by a two-week washout period (Figure 1). A 2-week washout system was
implemented to take into account the metabolism and excretion process, and the 2-day functionality of
the sterol in the human body [18].
Figure 1. Flowchart of the study participants.
Blood samples were taken at the beginning and at the end of each phase. Over a three-week
period, the subjects ingested two glasses of either type of milk daily. Each glass had a standard capacity
of 350 mL. Plant sterols were administered daily through the skim milk in quantities of 2.24 g (in
plant sterol phase), the same quantity of skim milk without plant sterol was used for the placebo.
An 80% target was set as the minimum threshold for consumption. Milk was packaged without
labelling to ensure neither the subjects nor the researchers were aware of the type of milk, and were
only differentiated by the lid’s colour. Groups were randomly assigned, using random number tables.
2.1. Sample Size
Of the 54 initial participants, 45 completed the genetic study: 25 women and 20 men with a mean
age of 37.9 ± 7.5 years. The sample was recruited based on total cholesterol as the primary biomarker,
according to the standard formulas for that purpose. The formula was calculated for a difference of
±15% of total cholesterol (200 mg/dL), taking into account a standard deviation of 35 mg/dL for a
confidence interval of 95%, a statistical power of 85%, and a loss rate of 10%, using the formula for
sample size.
2.2. Inclusion and Exclusion Criteria
Inclusion criteria: men and women, aged 18–50 years, with total cholesterol (TC) > 200 mg/dL.
Exclusion criteria: TC < 200 mg/dL, cardiac pathology (myocardial infarction, angina); lactose
intolerance, allergy to cow’s milk proteins or plant sterols; obesity (body mass index –BMI– >30) or
pharmacological treatment (for cholesterol or fibrate triglycerides, statins, etc.). Subjects that already
supplemented with plant sterols. None of the participants presented active thyroid disease, liver
disease, alcoholism, or any other such condition that dynamically altered lipid levels and/or diets.
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2.3. Clinical Analyses
The samples for the analytical tests were extracted by medical staff after a 12-h fast at the Clinical
Analysis Unit in the SCCUHM and El Escorial Hospital, and in the San Carlos Specialty Unit in San
Lorenzo de El Escorial.
The blood extraction protocol of the laboratory was as follows: blood extraction was
performed with a gel serum tube, using the technique ‘Blood collection’ with an s-Monovette in
aspiration [19–21]. After extraction, the samples were kept at 5 ± 3 ◦C until their arrival at the
laboratory. The centrifugation settings were T 20 ± 5 ◦C, for 10 minutes, at 1200 g. Stability: 1 week at
5 ± 3 ◦C. The Ultraviolet–Visible spectrophotometry technique was used.
The laboratory that performed the tests is located in the same city of the study, and has the
required legal accreditations, certificates, and standards, ISO 9001:2008, and accreditation 511/LE2114
according to criteria included in the UNE-EN ISO 15189 Standard.
2.4. Genetic
A variation in the effect of dietary treatment with plant sterols in milk on lipoprotein metabolism
(reduction of LDL-c) was observed; therefore, a genomic analysis was performed.
With this analysis, we sought to understand the following hypothesis: (1) that genetic
polymorphisms could be associated with a higher or lower response effect to the plant sterol treatment
for hypercholesterolemia.
Polymorphisms APOA5 C56G Ser19Trp, Prothrombin G20210A, F5 Arg506Gln, MTHFR C677T,
LIPC C-514T, LPA I4300M, PPAR_ALPHA L162V, APOA5 1131T>C, APOE APOE2/3/4 and APOE
APOE2,3,4 were studied.
Genomic DNA, for genotyping the SNP, was extracted from saliva samples. The analyses were
run by Vitagenes Lab (San Francisco, CA, USA). The genotyping was conducted using the Biobank
Axiom1 96-Array from Affymetrix. Genotype calling was performed with respect to Affymetrix’s best
practice guidelines, including analysis with SNPolisher, assuming a quality control rate of >0.97 [22,23].
The extraction and purification of DNA from saliva samples was carried out as follows: each DNA
extraction was run on an agarose gel to ensure high quality and high molecular weight. To ensure
maximum purity of the extracted DNA (ratio > 1.7), the OD260/280 ratio was analysed, that is,
the optical density of the extracted DNA at 260 nm and 280 nm wavelengths. All analyses were
performed in duplicate to ensure maximum precision and reliability in their results.
All Vitagenes analytical processes were carried out in laboratories that had CLIA certification,
thus attaining the optimal level of technical quality and precision proposed by the FDA in the United
States [24].
2.5. Variables and Study Factors
An ad hoc questionnaire was designed for the study. The questionnaire and anthropometric
study were performed by a single trained researcher, ensuring the homogeneity and standardisation
of the uniformity criteria and methodology to follow. The study variables were established in terms of
the proposed objectives: sex, age, clinical and pharmacological history, sleep quality, health habits,
use of tobacco and alcohol, intestinal transit, food consumption frequency, and physical activity.
In addition, each participant’s weight, height, waist perimeter, BMI, fat percentage, subcutaneous
fat percentage, and lean body mass (kg) were measured. Weight, BMI and body composition were
determined by means of tetrapolar multi-frequency (20 and 100 kHz) electrical bioimpedance, InBody
Model 230, following the usual standard protocol and the manufacturer’s recommendations [25].
Waist perimeter was measured with a flexible non-elastic metal measuring tape with a range of
0.1 mm–150 cm. Basal metabolic rate was calculated with the following formulas: BMR = 66 + (13.75
× weight in kg) + (5 × height in cm) − (6.8 × age in yrs), for men; BMR = 655 + (9.6 × weight
in kg) + (1.8 × height in cm) − (4.7 × age in Yrs), for women. The analytical markers were as
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follows: lipid profile (total cholesterol, high-density lipoprotein cholesterol (HDL-c), LDL-c, and
non-HDL-cholesterol. Confounding factors were also taken into account with an affinity table after
ingestion (>95%), monitoring of the non-modification of baseline habits during the trial, and a record
of food consumption frequencies; in order to control the ingestion of foods that may influence the
metabolism of cholesterol upwards or downwards.
2.6. Statistical Analysis
The data were analysed using the SPSS 21.0 statistical package. A descriptive analysis was first
made of the sociodemographic and anthropometric data, the baseline, and the final lipid values under
the ingestion of Naturcol and the placebo. The normality of the lipid values was determined using the
Shapiro–Wilk test. To analyse the efficacy of the ingestion of Naturcol and the placebo, the difference
in lipid values was calculated before and after ingestion, also applying the Student’s T-test, for related
samples, or the Wilcoxon rank sum test according to the compliance with the assumption of normality
of the dependent variables. The efficacy of the intervention was verified by comparing the differences
(final-baseline) in the ingestion of milk with sterols and the placebo, by applying the Student’s T-test
for related samples, or the Wilcoxon rank sum test depending on the compliance with the assumption
of normality of the lipid increase. The effect size and the proportion of the mean differences were
calculated with regard to the standard deviation of the baseline, or milk with sterols as the case may
be. The level of significance applied was 5%.
The study was approved by the respective bioethics committees of the San Carlos Clinical
University Hospital in Madrid (SCCUHM) and the El Escorial Hospital in Madrid.
This study followed the ethical principles enshrined in the Helsinki Declaration, the recommendations
for good clinical practice, current Spanish legislation regulating clinical research in humans, and the
protection of personal and bioethical data (Royal Decree 561/1993 on clinical trials and 14/2007, 3 July
for biomedical research).
3. Results
A total of 45 subjects (25 women and 20 men) completed the trial. Nine subjects failed to complete
the trial because of different genotyping, and failure to complete the plant sterols treatment (ingested
less than 80% of the consumption protocol). They had an average age of 37.9 ± 7.5 years and weighed
69 kg (BMI 23.7 kg/m2) (Table 1). Baseline total cholesterol was 236.6 mg/dL, LDL cholesterol was
157.3 mg/dL and HDL cholesterol was 58.2 mg/dL. There were no differences between centres in
volunteer demographics. In Table 2, the descriptive statistic of genes and haplotypes can be found.
Table 1. Descriptive statistics of the anthropometric measurements and lipid profile.
Total (n = 45) Males (n = 20) Females (n = 25)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 37.9 ± 7.5 39.7 ± 6.9 36.5 ± 7.8
Weight (kg) 68.6 ± 12.4 77 ± 11.3 61.4 ± 8.03
Height (m) 1.7 ± 0.1 1.76 ± 0.1 1.64 ± 0.1
BMI (Kg/m2) 23.7 ± 3.1 24.8 ± 3.2 22.8 ± 2.7
Body fat (%) 25.5 ± 7.3 21.2 ± 6.5 29.4 ± 5.7
Visceral fat (kg) 6.8 ± 4.6 8 ± 4.7 5.7 ± 4.3
Muscle (kg) 35.5 ± 13.4 40.4 ± 14.1 31.2 ± 11.4
Basal metabolic rate (kcal) 1484.5 ± 278.6 1705 ± 230.1 1285 ± 125.3
Decrease % (from baseline to final measures)
Total cholesterol (mg/dL) 9.1 ± 9.3 8.2 ± 9.8 9.9 ± 9.3
LDL-cholesterol (mg/dL) 11.8 ± 13.04 9.9 ± 12.9 13.4 ± 13.8
HDL-cholesterol (mg/dL) 1.8 ± 8.1 2.1 ± 6.9 1.5 ± 9.3
Non-HDL-cholesterol (mg/dL) 11.5 ± 10.8 9.6 ± 11.7 13.2 ± 10.3
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Table 2. Descriptive statistics of genes and haplotypes.
Gene Haplotype Frequency (n) Percentage (%)
APOA5 C56G Ser19Trp (rs3135506) CG 12 24.5
GG 37 75.5
Prothrombin G20210A (rs1799963) GG 49 100

















APOE Haplotipo APOE2/3/4 (rs429358) TT 42 85.7
TC 7 14.3
APOE Haplotipo APOE2,3,4 (rs7412) TC 7 14.3
CC 42 85.7
No statistically significant differences (p > 0.05) were found between the decreased percentage
of lipid parameters (total cholesterol, high-density lipoprotein cholesterol (HDL) cholesterol, and
Non-HDL cholesterol), and the genotypes observed for the following genes (Figure 2): MTHFR
C677T, LPA I4300M, PPAR_ALPHA L162V, APOA5 1131T>C, APOE APOE2/3/4 (p = 0.416) and
APOE APOE2,3,4.
Only APOA5 C56G Ser19Trp and LIPC C-514T genes incurred statistically significant changes
for levels of total cholesterol (p = 0.025; p = 0.005), but not HDL cholesterol (p = 0.032; p = 0.003),
respectively, after the treatment with sterols (Figure 2).
LIPC C-514T, APOA5 1131T>C and APOE APOE2/3/4 greatly benefit from sterol intake in the
diet (Figure 3). In LIPC C-514T carriers, TT homozygous and CT heterozygote carriers lowered their
LDL-c more than CC-homozygote carriers, after the ingestion of plant sterols (p = 0.001). APOA5
1131T>C and APOE APOE2/3/4 did not show statistically significant differences (p = 0.682; p = 0.416).
A large difference was also observed in the case of LPA I4300M and PPAR_alpha L162V genes,
between the carriers of the homozygous (TT and CC, respectively) and heterozygous (TC and CG,
respectively) variants, although the difference is not statistically significant (p = 0.121; p = 0.180).
Polymorphisms APOA5 C56G Ser19Trp, MTHFR C677T and APOE APOE2,3,4 exert a favourable
effect in the treatment, but no statistically significant differences in the reduction of LDL-c can be seen
(p = 0.246; p = 0.662; p = 0.637).
The analytical study could not be applied to Prothrombin G20210A and F5 Arg506Gln genes,
because each gene had only one haplotype.
After checking whether any genotype was directly related to baseline LDL-c, it was found that
only one of the analysed genes (APOA5 C56G Ser19Trp; p = 0.013) was associated with different rates
of baseline cholesterol, according to their single nucleotide polymorphism (SNP).
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Figure 3. Percentage difference in low-density lipoprotein (LDL) cholesterol values before treatment,
according to genes and haplotypes.
Other genes and their haplotypes could not be linked to a higher or lower level of basal cholesterol,
as measured by the parametric test, T-Student test or ANOVA. This means a possible protection of
this risk factor (LDL-c) could not establish by genotype. The obtained results for each gene were as
follows: MTHFR C677T (p = 0.184), LIPC C-514T (p = 0.522), LPA I4300M (p = 0.158), PPAR_ALPHA
L162V (p = 0.936), APOA5 1131T>C (p = 0.484), APOE APOE2/3/4 (p = 0.604), and APOE APOE2,3,4
(p = 0.233).
4. Discussion
Phytosterols are known to reduce serum LDL-c level without changing HDL-c levels. Daily
consumption of phytosterol-enriched foods is widely used as a therapeutic option to lower plasma
cholesterol and the risk of atherosclerotic disease [26]. Clifton et al. (2004) [27], who analysed the
differences of using plant sterols in different matrices, concluded that the matrix that had a better effect
in reducing LDL-c was obtained in milk.
When the recent scientific literature is reviewed, important studies [28] evaluating the benefit of
plant sterol consumption on cardiovascular risk biomarkers can be found, as a meta-analysis of more
than 40 clinical trials concluded [29].
Like other authors [29,30], this study analysed whether the effectiveness of plant sterols is
dependent on the subjects’ baseline levels; finding a higher decrease in LDL-c, the greater baseline,
depends on the subjects’ innate genes. Lipid metabolism, of great importance regarding cardiovascular
risk, is regulated by many genes whose variants may influence this risk [11].
Maasz et al. (2008) [31] suggested that the 56G allele can confer risk exclusively for the
development of large-vessel associated stroke. Thereby, the 56G allele differs from the APOA5T-1131C
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allelic variant, which has been previously identified as a risk factor for all subgroups of the stroke
disease, namely the C allele variant, which is a risk factor for heart disease and ischemic stroke [32,33],
by increasing levels of triglycerides. This polymorphism has a significant association with coronary
heart disease risk [34]. Sanchez-Moreno et al. (2011) [35] found that very low-density lipoprotein
cholesterol (VLDL-C) concentrations were higher in carriers of the minor allele than in noncarriers
(0.7 ± 0.32 vs. 0.6 ± 0.22 mmol/L) (p = 0.01).
Regarding the ApoE, it has been observed that the ε4 allele of the ApoE4 is a major risk factor for
coronary heart disease. However, the same results were not observed in the case of ApoE2, whose
polymorphisms did not seem significantly related to coronary risk [36].
The relationship between the hepatic lipase gene and the influence on HDL-c has not been clearly
established, although it seems to be an inverse relationship [8]. The influence that this gene has on the
metabolism of glycerophospholipids [37] may also alter plasma concentrations thereof. The results
published by Posadas-Sanchez et al. (2015) [38] suggest that the LIPC C-154T polymorphism is
associated with cardiometabolic parameters and cardiovascular risk factors: under the dominant
model, the TT genotype was associated with increased levels of the triglycerides/HDL-cholesterol
index (p = 0.046). On the other hand, the same genotype was associated with the presence of small LDLs
(p = 0.003). The risk analysis showed that under a dominant model, the LIPCC-514T polymorphism was
associated with increased hypertriglyceridemia (OR = 1.36, p = 0.006) and coronary artery calcification
(OR = 1.44, p = 0.015). The T allele carriers had higher levels of low-density lipoprotein cholesterol
(LDL-C) in obese boys, and TC and LDL-C in non-obese girls (all p < 0.05) [39].
Li et al. (2015) [36] exposed that for the C677T polymorphism, when compared with the wild
CC genotype, heterozygosity of CT increased the risk of congenital heart disease (OR = 2.249, 95%
CI 1.305–3.877, p = 0.003), and the homozygous mutant genotype TT was significantly associated with
the risk of congenital heart disease (OR = 3.121, 95% CI 1.612–6.043, p = 0.001).
The results suggested that genetic and metabolic biomarkers when used together may predict
inter-individual lipid level responsiveness to the plant-sterol-intervention, and thus could be useful
in devising individualised cholesterol-lowering strategies. We cannot find an accurate and concise
explanation, beyond the observation of these differences in the results, which should undoubtedly be
refuted until more research can corroborate our findings, and with samples of the wider population.
However, nutrigenomics has already observed these differences for years, as mutations in
some genes are known to hinder gene function, for example, in the classic studies of PUFAS and
Framingham [40–42]. It has not supposed a clinical transcendence as suggestive, as revealed by its
important results.
5. Conclusions
Having analysed the influence of different polymorphisms in hypercholesterolemia patients
following a dietary treatment with plant sterols, we can conclude that gene LIPC C-514T carriers,
especially TT homozygous carriers, lowered LDL-c more than CC homozygote and CT heterozygote
carriers, after ingestion of plant sterols. LIPC C-514T and APOA5 C56G Ser19Trp carriers greatly
improve their lipid profile from sterol intake in the diet. No statistically significant differences were
observed for other genes.
Human genome discoveries need to be moved into health practice in a way that maximises health
benefits and minimises harm to individuals and populations.
These results provide the basis for further studies to establish which genotype combinations
would be the most protective against hypercholesterolemia.
Limitations: The major limitation of this study was the sample size, which limited us from being able to extrapolate
the results to the Spanish population. A larger sample size would result in a sophisticated design and a greater
budget, that would limit the number of publications aligned in a deeper analysis.
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Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis,
steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with
advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma.
Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and
are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality
in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat
conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with
cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown
to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities
associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver
damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs,
as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering
drugs in patients with NAFLD.
Keywords: NAFLD; NASH; hepatic fibrosis; hyperlipidemia; statins
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in
the developed world, and can progress to cirrhosis and hepatocellular carcinoma [1]. It is also the
most common cause of elevated liver enzymes. Risk factors for NAFLD include obesity, diabetes
mellitus, and hyperlipidemia. Obesity is also a significant risk factor for NAFLD, independent
of hyperlipidemia, and weight loss has a beneficial effect on the prevention of hepatic fibrosis [2].
Patients with NAFLD are predisposed to cardiovascular mortality with studies demonstrating up
to a twofold increase in the risk of cardiovascular disease in this population [3]. There are several
hypotheses regarding the pathogenesis of NAFLD, which include insulin resistance, oxidative stress,
and lipotoxicity (Figure 1). Hyperlipidemia is a significant risk factor for NAFLD and associated
cardiovascular disease. The precise mechanism of action and the exact pathogenetic pathway on how
hyperlipidemia increases the risk of NAFLD has not been elucidated, but may be related to an increased
accumulation of lipids in the hepatocytes. Major sources of fatty acid delivery to hepatocytes include
splanchnic lipolysis of visceral fat, lipogenesis, and the ingestion of fatty foods. Insulin resistance also
downregulates low density lipoprotein (LDL)-receptor expression, leading to elevated levels of LDL.
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Multiple studies have shown the efficacy of lipid-lowering drugs in patients with NAFLD and its
subset non-alcoholic steatohepatitis (NASH). The aim of this article is to review the medical literature
on the utility of different anti-hyperlipidemic drugs in patients with NAFLD.
 
Figure 1. Pathogenesis of NAFLD/NASH and potential targets for treatment. HCC (Hepatocellular carcinoma).
2. Lipid-Lowering Drugs
2.1. Statins
Statins are the most widely used lipid lowering drugs due to their known efficacy in reducing
cardiovascular mortality in patients with coronary artery disease and diabetes mellitus. These
beneficial effects are not only due to the cholesterol-lowering ability of statins, but also due to their
anti-inflammatory, vasodilatory (statins are nitric oxide donor), vascular remodeling, and anti-fibrotic
effects independent of cholesterol-lowering activity. As inflammatory mechanisms are involved in
the pathogenesis of NAFLD/NASH, statins have shown promising results decreasing liver fibrosis in
patients with NAFLD. Generally, statins have been shown to be safe and effective treatment options
for the indication of dyslipidemia in the context of NAFLD with the exception of Child-Pugh B and C
cirrhosis and in particular if the total bilirubin level is greater than 3 mg/dL [4,5]. Table 1 summarizes
the current studies evaluating the utility of different statins in NAFLD and NASH.
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2.2. Simvastatin
Multiple studies have shown safety and efficacy results of simvastatin in patients with NAFLD
and NASH. Abel et al. conducted a study on a small group of NAFLD patients and revealed that
simvastatin at 20 mg/day for 6 months significantly decreased aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and LDL cholesterol levels in these patients [6]. Liver histological
evaluation was not done in this study. In another randomized controlled trial, simvastatin at
40 mg/day for 12 months was compared with a placebo, which significantly reduced LDL cholesterol
levels [7]. Although patient cholesterol levels were lowered in the simvastatin group, no significant
differences were found in levels of transaminases or hepatic fibrosis.
2.3. Atorvastatin
Several clinical studies reported the safety and efficacy of atorvastatin in NAFLD/NASH
patients [8–12]. A randomized controlled trial comparing atorvastatin with the combination of
atorvastatin and fenofibrate or fenofibrate alone revealed that atorvastatin alone or in combination with
fenofibrate could improve liver enzymes and ultrasonographic features of NAFLD [8]. In a St. Francis
Heart study, atorvastatin along with vitamins C and E was associated with reduced likelihood of
developing hepatic steatosis in patients with NAFLD [9]. Although the results of this study were
promising, they may be confounded by the use of vitamin E, as vitamin E alone has been shown to
be beneficial in NAFLD patients [19]. In a study by Gomez-Dominguez, 22 hyperlipidemic NAFLD
patients received 10–80 mg/day of atorvastatin for 6 months and showed significant improvement in
aminotransferase and cholesterol levels [10]. Kimura et al. reported the role of advanced glycation
end products (AGEs) in NASH, as the levels of these products were significantly high in NASH
patients. Treatment of patients with atorvastatin resulted in a significant decrease in AGE levels and
an improvement in metabolic parameters related to NASH [11]. In a study done on 27 biopsy-proven
NASH patients with hyperlipidemia, Kiyci et al. revealed the promising effects of atorvastatin
10 mg/day for 6 months [12]. Atorvastatin was shown to decrease aminotransferase activity and
significantly decrease fatty infiltration of the liver. These studies favor the beneficial effects of
atorvastatin in NAFLD patients.
2.4. Pravastatin
The current evidence regarding the use of pravastatin in NAFLD patients is lacking. In a
study on five patients with biopsy-proven steatohepatitis, Rallidis et al. revealed that the
use of pravastatin resulted in an improvement of hepatic histological findings [13]. Further
studies—especially randomized controlled trials—are needed to further investigate the utility of
pravastatin in NAFLD patients.
2.5. Pitavastatin
Pitavastatin has been indicated to be beneficial in inhibiting hepatic fibrosis in NASH rat models,
but research on its utility in patients with NAFLD is still too premature to make any conclusions.
Hyogo et al. conducted an open-label pilot study that revealed 2 mg/day of pitavastatin for 12 months
decreased the severity of hepatic steatosis and NASH-related parameters [14]. Although the study
results are promising, further studies are necessary to support these findings.
2.6. Lovastatin
In a multicentric prospective study, 10 mg/day of lovastatin for four months was shown
to significantly decrease transaminases, cholesterol levels, and aminotransferase to platelet ratio
indices [15]. Again, more studies are needed to support the beneficial effects of lovastatin in
NAFLD patients.
38
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2.7. Rosuvastatin
In a preliminary report on six patients with NASH, 10 mg/day of rosuvastatin for 12 months not
only showed improvement in AST and ALT levels, but also the complete resolution of ultrasonographic
findings of NASH in five patients [16]. Similar beneficial effects were seen in a prospective study on
20 patients, in which 10 mg/day of rosuvastatin for 12 months resulted in the complete resolution
of ultrasonographic findings of NASH in 19 patients [17]. Nakahara et al. also revealed beneficial
effects of 2.5 mg/day of rosuvastatin for 24 months, and showed an improvement of NASH-related
parameters and histological features in some patients [18].
2.8. Non-Statin Lipid Lowering Drugs
Table 2 summarizes the current evidence regarding the utility of lipid-lowering drugs other than
statins in patients with NAFLD and NASH.
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2.9. Fibrates
Fibrates or fibric acid derivatives are used to treat hypertriglyceridemia and primary
hypercholesterolemia, mainly by activating peroxisome proliferator-activated receptor alpha
(PPAR-alpha). Multiple studies have been done to evaluate the safety and efficacy of these agents in
treating hyperlipidemia in NAFLD/NASH patients [8,20–22]. In a prospective open-label randomized
study, Athyros et al. included 186 patients that were randomly assigned to receive either 20 mg/day
of atorvastatin, 200 mg/day of fenofibrate, or both [8]. A complete resolution of biochemical and
ultrasonographic evidence of NAFLD was seen in 42% of the patients in the fenofibrate group compared
to 67% of patients taking atorvastatin alone, and 70% in the combination therapy group [8]. In a
randomized controlled trial (RCT), Basarangolu et al. included 23 patients taking 600 mg/day of
gemfibrozil for four weeks, and compared these with 23 placebo patients who were not treated with
any lipid-lowering drugs. Patients in the gemfibrozil group had significantly lower levels of AST, ALT,
and GGT without any significant changes in liver histology [20]. Laurin et al. evaluated the utility
of the fibric acid derivative clofibrate in 16 NASH patients with hyperlipidemia taking 2 g /day [21].
The study did not find any improvement in aminotransferases, GGT, or bilirubin levels. In a pilot
study on 16 biopsy-proven NAFLD patients, Fernandez-Miranda et al. revealed that 200 mg/day of
fenofibrate for 48 weeks resulted in decreased insulin resistance, aminotransferases levels, and signs of
metabolic syndrome [22]. Although the drug showed promising results in decreasing the proportion
of patients with metabolic syndrome, its effect on liver histology was minimal. Hence, considering
current evidence, we conclude that the utility of fibrates and fibric acid derivatives in ameliorating the
histological features of NAFLD is still unclear and requires further studies.
2.10. Elafibranor
Elafibranor is an activator of both Peroxisome proliferator-activated receptor (PPAR)-α and
PPAR-δ that has anti-inflammatory effects and helps to improve lipid metabolism and insulin resistance.
In a randomized controlled double-blind trial, 276 patients with NASH were divided into three groups
to receive either 80 mg/day of elafibranor, 120 mg/day of elafibranor, or a placebo for 52 weeks [23].
Aminotransferase activity, glucose levels, and inflammatory markers were significantly lower in the
elafibranor 120 mg group compared to the placebo group. A post-hoc analysis of the study also
revealed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening in the
greater proportion of patients compared to placebo, but there was no difference in the outcome in
the intention-to-treat analysis [23]. These results are encouraging for the use of elafibranor in NASH
patients, but require further studies—especially randomized controlled trials—to further strengthen
the evidence of these beneficial effects.
2.11. Niacin
Niacin (nicotinic acid or vitamin B-3) is used to treat vitamin deficiency (pellagra) and has
lipid-lowering effects. The mechanism by which these drugs exert their lipid-lowering effects is still
unclear. Fabbrini et al. reported that the combination of 200 mg/day of fenofibrate for 8 weeks and
extended-release niacin at 2000 mg/day for 16 weeks lowered the plasma levels of VLDL-triglycerides,
but did not alter intrahepatic triglyceride content [24]. The safety and efficacy of niacin in NAFLD
patients has yet to be established, and requires further clinical studies.
2.12. Ezetimibe
Ezetimibe exerts its lipid-lowering effects by inhibiting small intestinal absorption of cholesterol
via its effects on the sterol transporter Niemann–Pick C1-Like1 (NPC1L1). These molecules are also
expressed in the liver, and play a role in hepatic cholesterol accumulation. The combination of ezetimibe
and statins has been shown to improve LDL cholesterol levels in patients with hypercholesterolemia.
In one study, Yoneda et al. reported 10 mg/day of ezetimibe for 6 months in NASH patients with
41
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hyperlipidemia resulted in significant improvement in histological findings, NAFLD activity scores,
and steatosis in the liver [25]. They also revealed improvement in AST, ALT, GGT, LDL cholesterol
levels, and C-reactive protein (CRP) in these patients. Similar results were seen in a study done by
Park et al. regarding 45 patients with biopsy-proven NAFLD [26]. They reported that 10 mg/day
of ezetimibe for 24 months improved the biochemical and histological abnormalities of NAFLD.
Chan et al. also reported that weight loss along with ezetimibe was associated with an improvement
in hepatic steatosis [27]. These study results favor the use of ezetimibe in NAFLD/NASH patients
with hyperlipidemia, as it might ameliorate the biochemical and histological features of NAFLD.
2.13. Omega-3 (n-3) Polyunsaturated Fatty Acids (PUFAs)
The use of n-3 PUFAs increases the levels of adiponectin in the blood and decreases serum levels
of triglycerides, leptin, and insulin, which promote weight loss and improve insulin resistance [28,29].
In a study of 40 patients with NAFLD, Spadro et al. reported improvement in serum AST, ALT,
triglyceride levels, and fatty liver with the use of n-3 PUFAs [28]. Similar beneficial effects were seen
in a study by Capanni et al., which reported that n-3 PUFA supplementation of 1 g/day for 12 months
resulted in the improvement of AST, ALT, GGT, triglycerides, and ultrasonographic features of hepatic
steatosis [29]. Current evidence is therefore encouraging, but further studies are needed to define the
utility of n-3 PUFAs for management of NAFLD.
3. Conclusions
Statins have been shown to be most beneficial in the prevention of hepatic fibrosis in patients with
NAFLD/NASH. Hence, in light of current evidence, we recommend considering statins and vitamin
E along with weight loss and exercise in these patients. Although evidence regarding the utility of
lipid-lowering drugs in patients with NAFLD/NASH is convincing, with most studies reporting that
lipid-lowering drug use showed an improvement in hepatic steatosis, formal guidelines are lacking
in this regard—mainly due to the absence of larger randomized controlled trials. Despite the need
for more randomized controlled trials regarding these drugs, our review will help guide clinicians in
prescribing lipid-lowering agents in NAFLD patients. This, in turn, may help decrease the morbidity
and mortality associated with this serious disease.
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Abstract: The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease
which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal
degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be
controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on
the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal
antibodies directed against PCSK9, given on a background of statin therapy, have been shown to
markedly decrease LDL-C levels and significantly reduce cardiovascular risk. The small interfering
RNA (siRNA) molecules have been used recently to target the hepatic production of PCSK9. siRNA
interferes with the expression of specific genes with complementary nucleotide sequences by affecting
the degradation of mRNA post-transcription, thus preventing translation. Inclisiran is a long-acting,
synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic
production of PCSK9 and cause a marked reduction in LDL-C levels. This review aims to present and
discuss the current clinical and scientific evidence pertaining to inclisiran, which is a new promising
agent in the management of hypercholesterolemia.
Keywords: proprotein convertase subtilisin-kexin type 9 (PCSK9); small interfering RNA
(siRNA); inclisiran; low-density lipoprotein-cholesterol (LDL-C); cardiovascular disease (CVD);
cardiovascular risk
1. Introduction
Cardiovascular disease (CVD) is the number one cause of death worldwide. An estimated
17.7 million people died from CVD in 2015, representing 31% of all global deaths [1].
Hypercholesterolemia is a major known risk factor for cardiovascular disease and low-density
lipoprotein cholesterol (LDL-C) lowering has been unequivocally shown to cause a significant reduction
in cardiovascular risk in both primary and secondary prevention [2,3]. Statins are the standard of care
and have a proven efficacy in LDL-C lowering and in the reduction of CVD risk [4,5]. However, there
is considerable variability in individual responses to statins [6] and many individuals at risk for CVD
fail to achieve LDL-C goals [7,8]. Furthermore, several patients demonstrate intolerance to statins,
mostly due to myalgias and weakness [9]. These factors necessitate research for the development of
Diseases 2018, 6, 63; doi:10.3390/diseases6030063 www.mdpi.com/journal/diseases45
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new additional therapies with a favorable side effect profile that would improve our ability to achieve
LDL-C goals and decrease CVD risk [10].
The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9) in 2003 [11], a serine
protease which binds to the LDL receptors and targets the receptors for lysosomal degradation,
thereby reducing their recycling and decreasing the removal rate of circulating LDL-C [12], offered an
additional route through which plasma LDL-C levels can be controlled [13]. Initially, the therapeutic
approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies.
To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9,
given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and
significantly reduce cardiovascular risk [14,15]. Circulating PCSK9 is generated mainly by the liver;
hence, therapeutic agents curtailing the hepatic production of PCSK9 may provide an alternative to the
use of monoclonal antibodies. Inclisiran is a chemically synthesized small interfering RNA (siRNA)
molecule, which targets the hepatic production of PCSK9 and is currently under investigation for its
LDL-C lowering effect and potential for cardiovascular risk reduction.
2. siRNAs: Mechanism of Action
siRNAs are ~20–30 nucleotide RNA molecules, which lately have emerged as critical regulators
in the expression and function of eukaryotic genomes. These molecules, which may be active in both
the somatic and germline lineages of different eukaryotic species, are involved in the regulation of
endogenous genes and in the protection of the genome from invasive nucleic acids [16]. In most
mammalian cells, long double-stranded RNA induces an interferon response, which contributes to
the antiviral defense. This interferon response prompts a generalized shutdown of protein synthesis.
As a result, long double-stranded RNA cannot be used for specific gene silencing. On the contrary,
siRNAs can evade the radar of the mammalian interferon response and produce strong and specific
gene silencing [17]. More specifically, siRNA interferes with the expression of specific genes with
complementary nucleotide sequences by affecting the degradation of mRNA post-transcription,
thus preventing translation [18].
3. Inclisiran
The siRNA molecule has been used recently to decrease PCSK9 levels. The siRNA molecules
follow the natural pathway of RNA interference (RNAi) by binding intracellularly to the RNA-induced
silencing complex (RISC), thus enabling it to cleave messenger RNA (mRNA) molecules specifically
encoding PCSK9 [19].
Inclisiran is a long-acting, synthetic siRNA directed against PCSK9, which is conjugated
to triantennary N-acetylgalactosamine carbohydrates. These carbohydrates bind to abundant
liver-expressed asialoglycoprotein receptors, leading to the uptake of inclisiran specifically into the
hepatocytes [20,21].
A schematic of the mechanism of action of inclisiran (along with the action of PCSK9, the hepatic
production of which is significantly decreased by inclisiran) is shown in Figure 1.
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Figure 1. Mechanism of action of inclisiran in conjunction with the action of PCSK9.
4. Clinical Trials with Inclisiran
In a randomized, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy
adult volunteers with serum LDL-C levels ≥ 3.00 mmol/L (116 mg/dL), participants were randomly
assigned in a 3:1 ratio to receive one dose of intravenous ALN-PCS (inclisiran), with doses ranging
from 0.015 to 0.400 mg/kg, versus placebo. In the group of participants who received treatment
with inclisiran at the dose of 0.400 mg/kg, there was a significant mean reduction in circulating
PCSK9 and LDL-C levels by 70% and 40%, respectively, as compared with placebo (p < 0.0001 for both
comparisons). The proportions of patients affected by treatment-emergent adverse events were similar
in the inclisiran and placebo groups (79% vs. 88%, respectively) [22].
In another phase 1 trial, several different doses of inclisiran or placebo were administered
subcutaneously to healthy volunteers with an LDL-C level of at least 100 mg/dL. The doses of
inclisiran tried were single-dose-injections (25, 100, 300, 500, and 800 mg) or multiple-dose injections
(125 mg weekly for four doses, 250 mg every other week for two doses, and 300 or 500 mg monthly for
two doses) with or without concurrent statin therapy. Single doses of inclisiran ≥ 300 mg decreased
the PCSK9 level by up to a least-squares mean reduction of 74.5% from baseline to day 84, whereas
single doses of ≥100 mg lowered LDL cholesterol-C by up to a least-squares mean reduction of 50.6%
from baseline. Reductions in the PCSK9 and LDL-C levels were maintained at day 180 for doses of
≥300 mg. All multiple-dose regimens of inclisiran reduced the levels of PCSK9 and LDL-C by up to a
least-squares mean reduction of 83.8% and 59.7% from baseline to day 84, respectively. There were no
serious adverse events observed with inclisiran and the most common adverse events were cough,
musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea [23].
ORION-1 was a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose
trial of inclisiran, administered as a subcutaneous injection, in patients at high risk for CVD with
LDL-C levels > 70 mg/dL in the presence of a history of atherosclerotic CVD (ASCVD) or > 100 mg/dL
in the absence of a history of ASCVD. A total of 501 patients were randomly assigned to receive a
single dose of placebo or 200, 300, or 500 mg of inclisiran, or two doses of placebo or 100, 200, or 300 mg
of inclisiran at days 1 and 90. The primary end point was the change in LDL-C level from baseline
level at 180 days. At enrollment, 73% of the patients were on statin therapy, and 31% of the patients
were on treatment with ezetimibe. At day 180, the least-squares mean reductions in LDL-C levels
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were 27.9 to 41.9% in the patients who received a single dose of inclisiran and 35.5% to 52.6% in the
patients who received two doses (p < 0.001 for all comparisons vs. placebo). The greatest reduction
in LDL-C levels was attained with the two-dose 300-mg inclisiran regimen and 48% of the patients
who received that regimen had an LDL-C level < 50 mg/dL at day 180. Furthermore, the two-dose
300-mg inclisiran regimen caused a least-squares mean reduction in PCSK9 levels by 69.1% (p < 0.001
vs. placebo) and decreased high sensitivity C-reactive protein (hsCRP) by 16.7% (p < 0.05). Serious
adverse events occurred in 11% of the patients who received inclisiran and in 8% of the patients who
received placebo. Injection-site reactions occurred in 4% of patients who received one dose and in 7%
of patients who received two doses of inclisiran [24]. Thus, in this phase 2 trial, inclisiran produced
significant reductions in LDL-C and PCSK9 levels with an acceptable side effect profile, as compared
to placebo. However, given the relatively small number of patients and the short duration of the study,
no definitive conclusions can be drawn regarding the long-term side effect profile of inclisiran and
further larger studies with a longer follow-up period are required for that reason.
ORION-11 is an ongoing placebo-controlled, double-blind, randomized, phase 3 trial with
inclisiran. The study will enroll individuals with ASCVD or ASCVD-risk equivalents and elevated
LDL-C despite maximum tolerated dose of LDL-C lowering therapies in order to evaluate the efficacy,
safety, and tolerability of subcutaneous inclisiran injection(s). The study will be an international
multicenter study (non-United States). Currently, 1617 participants have been enrolled. The patients
will be randomly assigned to either inclisiran or placebo. Doses of 300 mg of inclisiran sodium
(equivalent to 284 mg of inclisiran) will be administered as subcutaneous injections on day 1, day 90,
and then every 6 months. Primary outcomes include percentage change in LDL-C from baseline to
day 510 and time-adjusted percent change in LDL-C levels from baseline between day 90 and day 540.
The secondary outcomes include absolute change in LDL-C from baseline to day 510, time-adjusted
absolute change in LDL-C from baseline between day 90 and day 540, as well as the percentage changes
in the levels of PCSK9, total cholesterol, apolipoprotein B (ApoB), and non-high-density lipoprotein
cholesterol (non-HDL-C) from baseline to day 510 [25].
ORION-11 trial is one of the four phase 3 pivotal trials with inclisiran. Others include the
ORION-10 trial with approximately 1500 ASCVD patients in North America, the ORION-9 trial with
approximately 400 patients with heterozygous familial hypercholesterolemia (FH) in North America,
Europe, Israel, and South Africa, as well as the ORION-5 trial with 60 patients with homozygous FH
in Europe, Middle East, and North America [26].
5. Conclusions and Future Directions
Medical interventions targeting PCSK9 have emerged as a very promising therapeutic strategy in
the management of hyperlipidemia. By inhibiting the expression of PCSK9, significant reductions in
the levels of LDL-C have been obtained that may lead to a reduction of cardiovascular risk [20]. As it
was mentioned before, two PCSK9 inhibitors (evolocumab and alirocumab) have already been tested
in large outcome trials and have been shown to significantly decrease cardiovascular risk [14,15].
On the other hand, inclisiran, a synthetic siRNA molecule, has been shown to significantly
decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels [22–24], although,
up to date, there are no available studies showing the effect of inclisiran on intermediate CVD markers,
such as intima-media thickness of the carotid artery (CIMT), arterial flow-mediated dilation (FMD),
or arterial pulse wave velocity (PWV). Advantages of inclisiran over monoclonal antibodies directed
against PCSK9 include its infrequent administration (twice a year vs. 12–26 injections per year for
PCSK9 inhibitors), as well as the fact that anti-PCSK9 monoclonal antibodies act at a plasma level,
whereas inclisiran acts at the intracellular level of hepatocytes to mitigate the levels of LDL-C and
PCSK9 [27].
Furthermore, inclisiran appears to have a relatively benign side effect profile, as shown in the
ORION-1 trial. There were only rare symptoms of immune activation, such as flu-like symptoms,
which is often a concern with RNA-targeting therapies. In addition, inclisiran did not adversely affect
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platelet levels, in contrast to other recent reports from studies of antisense oligonucleotides and other
siRNA molecules [24,28]. However, the ongoing ORION-11 trial [25] is expected to better define the
long-term side effect profile of inclisiran.
Notwithstanding, it is not yet ascertained that the marked LDL-C reductions attained with
inclisiran would definitely translate into a reduction in CVD risk, and thus, large outcome trials would
need to be conducted in the future for that reason.
Other potential future therapeutic strategies targeting PCSK9, which are currently in the initial
stages of development, include small molecule inhibitors that disrupt the processing of PCSK9, the
use of adnectins, which block the binding of PCSK9 to the LDL receptor [20,29], as well as the AT04A
vaccine, which is currently being tested in a phase 1 clinical trial [20,30].
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Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce the risk of
cardiovascular events and all-cause mortality in patients at high risk of cardiovascular disease
(CVD). Due to high costs and unknown long-term adverse effects, critical evaluation of patients
considered for PCSK9 inhibitors is important. It has been proposed that measuring low-density
lipoprotein (LDL) subfractions, or LDL particle numbers (LDL-P), could be of value in CVD risk
assessment and may identify patients at high risk of CVD. This review evaluates the evidence for the
use of LDL subfractions, or LDL-P, when assessing CVD risk in patients for whom PCSK9 inhibitors
are considered as a lipid-lowering therapy. Numerous methods for measuring LDL subfractions
and LDL-P are available, but several factors limit their availability. A lack of standardization makes
comparison between the different methods challenging. Longitudinal population-based studies have
found an independent association between different LDL subfractions, LDL-P, and an increased risk
of cardiovascular events, but definitive evidence that these measurements add predictive value to the
standard risk markers is lacking. No studies have proven that these measurements improve clinical
outcomes. PCSK9 inhibitors seem to be effective at lowering all LDL subfractions and LDL-P, but any
evidence that measuring LDL subfractions and LDL-P yield clinically useful information is lacking.
Such analyses are currently not recommended when considering whether to initiate PCKS9 inhibitors
in patients at risk of CVD.
Keywords: PCSK9; proprotein convertase subtilisin/kexin type 9; LDL subfractions; sdLDL;
cardiovascular disease; risk stratification
1. Introduction
Despite major advances in the prevention and treatment of cardiovascular diseases (CVD) over
the last few decades, CVD continues to be the leading global cause of death and morbidity [1]. Several
different guidelines for CVD prevention are available and the recommended overall strategy is the
targeting of modifiable risk factors in high risk patients [2,3].
Of the multiple modifiable risk factors associated with cardiovascular disease [4], low-density
lipoprotein (LDL) is the most intensively studied and a causal relationship with the development
of CVD has been established [5]. Managing LDL-related risk is emphasized in all CVD prevention
guidelines by recommending lipid-lowering therapy, usually statins, to all patients for secondary
prevention, and to high-risk patients for primary prevention [6]. The guidelines for CVD prevention are
not unified in their recommendations on what lipoprotein measurement to use in risk assessment and
as a target of therapy [2,3,7]. Non-high-density lipoprotein cholesterol (non-HDL-C) is the lipoprotein
measurement recommended for risk assessment in most guidelines, as it reflects all the cholesterol mass
with atherogenic potential and avoids the biases that might arise when using the Friedewald formula
to calculate LDL cholesterol (LDL-C) [8]. LDL-C is still the most widely-recommended primary target
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of therapy. Both metrics are included in the standard lipid panel, which is readily available at most
clinical laboratories. Despite its central role in CVD pathophysiology, the value of both non-HDL-C
and LDL-C in CVD risk stratification is limited as a significant proportion of patients who develop
CVD have levels within the “normal” range [9]. Due to this, there has been intensive research into
whether different advanced lipoprotein testing methods may improve cardiovascular risk prediction.
LDL-C is a measure of the total cholesterol content in LDL particles. LDL-C and LDL particle
number (LDL-P) is usually highly correlated [10]. Under certain circumstances, notably in patients with
diabetes, metabolic syndrome, or hypertriglyceridemia, LDL-C and LDL-P can become discordant due
to the predominance of small dense cholesterol-depleted LDL-particles (sdLDL) [11]. In these patients,
LDL-C might not accurately reflect the LDL-related risk for cardiovascular disease, and studies have
shown that LDL-P has a stronger association with CVD risk compared to LDL-C in patients with
discordant levels of LDL-C and LDL-P [10,11]. Due to this fact, it has been proposed that measuring
subfractions or the particle number of LDL, might enhance CVD risk assessment in the general
population and detect residual risk in patients already receiving lipid-lowering therapy.
Recent advances in lipid lowering therapies, with the development of proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors [12], has reignited attention on CVD-risk stratification.
Clinicians now have the tools to reduce LDL to very low levels, but the costs are significant and
potential side effects have only been evaluated in relatively short-term studies. For this reason, PCKS9
inhibitors are currently only recommended to patients at a very high risk, such as patients with
familial hypercholesterolemia (FH), statin-intolerant patients in secondary prevention, or in secondary
prevention for patients with high residual risk [13,14].
In this review, we sought to evaluate the evidence for the use of LDL subfractions in CVD risk
assessment in general, and to assess if the available methods for LDL subfractioning could be of value
for clinicians in the decision of whether to initiate PCKS9 therapy in patients.
2. LDL Subfractions—And How to Separate Them
LDLs are broadly defined as lipoproteins with a density in the range of 1.019–1.063 g/mL, and each
particle containing one apolipoprotein B (apoB) molecule (Figure 1). LDL particles are heterogeneous
with respect to size, density, and composition, and can be separated based on various physicochemical
properties depending on the protein purification technique used. The methods commonly used in
the published literature on LDL subfractions are usually based on gel electrophoresis (GE), nuclear
magnetic resonance (NMR), ultracentrifugation (UC), or ion mobility (IM), but several other methods
are also available [15,16].
The accessibility of these methods is limited. GE, NMR, UC, and IM are technically demanding,
expensive, and too labor-intensive for routine use in clinical laboratories. Most methods used in
published studies are patented laboratory developed tests, which are only available at one laboratory
or a limited number of laboratories. Two exceptions include a simple and less-expensive tube gel
electrophoresis-system (Lipoprint®) [17] and a homogeneous assay (HA) adaptable to autoanalyzers [16].
The different methods use various terms to describe LDL particles, their distribution,
and characteristics, including: LDL subfractions, LDL subclasses, LDL particle and subfraction
concentration, LDL particle diameter, LDL peak diameter, and others [18–20]. These terms describe
overlapping attributes of the LDL particles. The potential for confusion is significant, and in this
review we will use the generic term LDL subfractions. LDL particle number (LDL-P) is a measurement
of the total number of LDL particles across all subfractions, but will be included in this review as NMR
and IM methods report it. ApoB is another indirect measurement of LDL-P and the ratio between
serum cholesterol and apoB has been proposed as a metric to determine the prevalence of sdLDL [21].
However, apoB will not be included in this review as apoB is not reported by the various methods that
determine LDL subfractions.
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Figure 1. Relative size and density of the major plasma lipoproteins and their subfractions.
The recognition of the different LDL subfractions has led to the description of two distinct patterns
of phenotypes that are reported by most LDL subfractioning methods available today [22]: Phenotype
“A”, with a predominance of large buoyant LDL-particles and phenotype “B”, with a predominance of
small, dense LDL particles, which is suggested as a more atherogenic phenotype.
3. Comparability of Methods for LDL Subfractioning
Presently, there is no method for the determination of LDL subfractions that is considered
a reference or a gold standard. The different methods commonly available (NMR, UC, GE, and IM)
separate LDL particles based on different characteristics that are not directly comparable; GE separates
LDL particles based on size and charge, UC based on density, NMR measures methyl group signals
from lipoprotein particles and calculates the LDL particle number and size, while IM separates
lipoprotein particles using gas-phase electrophoresis and directly counting the size-separated particles.
In 2009, Chung et al. [23] published a comprehensive review of the comparability between several
different methods for LDL subfractioning, including UC, NMR, and segmented gradient GE (sGGE).
This review raised several issues. These methods separate LDL particles based on completely different
physicochemical properties, and, consequently, it is not possible to determine whether the different
methods are measuring the same subfractions. Different thresholds of LDL size and particle number
are used to describe LDL particle distributions and LDL phenotypes, further obfuscating a reasonable
comparison of results between methods. Furthermore, the wide range of agreement between the
methods reported (7–94% concordance for classifying LDL phenotypes) was suggested to be due to
a lack of standardization. Lastly, no study has compared the diagnostic accuracy, efficacy, or clinical
value of these methods to individuals’ clinical outcomes.
Chung et al. concluded that, to permit an accurate description of the similarities and differences
among the different LDL subfractioning methods, a reference material, accepted as appropriate,
accurate and reliable, needed to be developed. After the establishment of a consensus reference
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method, epidemiological studies and clinical trials are required to examine the clinical value of LDL
subfractioning to predict the individual patients’ clinical outcomes [23].
Since 2009, no reference material, nor a consensus reference method, has been established.
IM has been introduced and has been used in the larger population-based studies [24,25], adding
to the complexity of LDL subfractioning. A few studies, published since 2009, have looked at
the comparability between different methods. Two studies have reported high rates of correlation,
including a 98% agreement between IM and sGGE [26,27], but as a healthy study population was used
the results need to be confirmed in a population relevant for CVD risk assessment. Williams et al.
reported that both sGGE, NMR, and IM confirmed the association between small LDL particles and
greater atherosclerotic progression, but the correlations between the methods varied significantly [28].
In contrast, international standards exist for assays measuring HDL-C, total cholesterol, LDL-C,
apoB and apolipoprotein A1, and Lipoprotein(a). [29]
4. The Atherogenicity of Small, Dense LDL Particles
The first step in the initiation of atherosclerotic disease is the subendothelial retention of
apoB-containing lipoproteins, predominantly LDL, in the arterial wall [30]. Elevated levels of
apoB-containing lipoproteins in the blood increases the risk of atherosclerotic disease, in a dose-dependent
matter [31]. One possible explanation for increased CVD risk associated with elevated levels of sdLDL or
LDL-P could be that these measures more accurately reflect the number of apoB-containing lipoproteins
compared to LDL-C.
There is also evidence indicating that sdLDL-particles have an increased atherogenic potential
when compared to larger LDL particles [32]. The circulation time of sdLDLs is proposed to be longer,
compared to larger LDL-particles, due to their impaired interaction with the LDL-receptor (LDLR) [33].
An increased susceptibility of sdLDL to undergo atherogenic modification in blood plasma, such as
desialyation, glycation, and oxidation, has also been reported [34,35] and in-vitro studies have shown
that sdLDL particles are more avidly taken up by macrophages, have a greater propensity for transport
into the artery wall, and have a greater binding potential to proteoglycans in the artery wall [36,37].
5. LDL Subfractions and Associations with Increased CVD Risk
Ip et al. published a systematic review of associations between LDL subfractions and
cardiovascular outcomes in 2009 [38]. Most trials (37 of 52) found statistically significant associations
between LDL subfraction size, number or phenotype, and cardiovascular outcomes. However,
only 26 analyses were adjusted for standard lipids and just 12 of the adjusted studies found significant
associations with incident cardiovascular disease, including 4 of the 14 trials analysing LDL size and
sdLDL, and 8 of the 12 trials analysing LDL number and phenotype. Several important limitations
were noted, including the lack of comparability between the various methods used to measure LDL
subfractions and a heterogeneity in the adjustment and small sample sizes. The review concluded that
there is a potential association between small LDL subfractions and incident cardiovascular disease,
but there is not enough data to support their value as an independent risk factor for clinical use.
Standardization of LDL subfractions measures is needed and studies need to confirm that treatment
based on LDL subfraction testing is beneficial.
Since 2009, several large population-based longitudinal studies have investigated the association
between various LDL subfractions and cardiovascular outcomes (Figure 2).
Mora et al. (2015) [24] published a study based on clinical data and blood samples from the
JUPITER-study [39]; a large, randomized prospective trial of rosuvastatin for primary CVD prevention
in patients with LDL-C levels less than 130 mg/dL (<3.34 mmol/L) and elevated hsCRP. IM was
used to determine the LDL subfractions. They included 11,186 participants, 5600 in the placebo arm,
and 199 primary CVD events were recorded in the placebo group. Mean follow-up time was only
1.9 years as the trial was terminated early. In the placebo-arm of the study, several of the smaller
LDL subfractions showed significant associations with an increased risk for incident CVD in a top vs.
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bottom tertile analysis, which used a model that did not adjust for standard lipids (Figure 2). In a fully
adjusted model including standard lipids, only one of the smaller LDL subfractions (LDL-Very small
(c)) remained significantly associated with an increased CVD risk.
Shiffman et al. (2017) [25] and Melander et al. (2015) [40] published studies based on data and
blood samples from the Malmö Prevention Project (MPP), a large population-based prospective study.
Shiffman et al. included 5764 participants without CVD as a baseline, and recorded 1784 CVD events
over a mean follow-up time of 8.05 years. Melander et al. included 1919 participants who were not
candidates for statin therapy, as defined in the 2013 American Heart Association/American College
of Cardiology guidelines for the treatment of cholesterol to reduce CVD risk, and, thus, were at low
risk for a CVD event. During a mean follow-up of 16.2 years, they recorded 88 CVD events (4.8%).
Both studies used IM as the method for the determination of LDL subfractions.
Figure 2. Associations between low-density lipoprotein (LDL) subfractions and cardiovascular
disease (CVD) reported in prospective population-based studies published after 2009 and adjusted for
confounding factors, such as age, smoking, gender, hypertension, etc. a Top vs. bottom quartile analysis.
b Top vs. bottom tertile analysis. c Not significant in a model adjusted for lipids. d 1st vs. 2nd quartile
analysis. e 1st vs. 3rd quartile analysis. f 1st vs. 4th quartile analysis. g Associations with CVD in
patients with discordant levels of LDL particle number (LDL-P), apolipoprotein B (apoB), non-high
density lipoprotein cholesterol (non-HDL-C) (≥median), and LDL cholesterol (LDL-C) (<median).
h Hazard ratio (95% CI) pr. 1 SD higher. Hazard ratios for the outcome “major occlusive event” in the
placebo arm are depicted in the graph.
Shiffman et al. reported that two of the five Small or Very Small LDL-subfractions were
significantly associated with an increased risk for a CVD event in a top vs. bottom quartile analysis
using a fully, lipid adjusted model. (Figure 2). LDL-P was not associated with an increased CVD
risk. In a subgroup analysis of patients with low to intermediate risk, LDL-P and the LDL-Small
subfraction was significantly associated with an increased risk, while in participants at very high risk
(>20% 10-year risk), LDL-P and four of the five LDL subfractions were significantly associated with
an increased risk.
Melander et al. reported that the LDL-P and the LDL-Small subfractions were associated with
an increased risk of incident CVD in a fully, lipid adjusted, top vs. bottom tertile analysis, while the
other four LDL-Very Small subfractions were not (Figure 2).
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Hoogeveen et al. (2014) [41] published a study based on data and blood samples from the
Atherosclerosis Risk in Communities (ARIC) study, a large population-based prospective study.
They included 10,225 participants without prevalent CVD. Mean follow-up time was 11 years and
incident CVD developed in 1158 participants. LDL subfractions were determined by a homogenous
assay that quantified small, dense LDL-C (sdLDL-C). [16]. sdLDL-C was significantly associated with
incident CVD in a top vs. bottom quartile analysis using a model that did not adjust for standard lipids
(Figure 2), In a fully adjusted model that included standard lipids sdLDL-C was not associated with
an increased risk. The cumulative incidence of CVD was higher in participants with low LDL-C and
discordantly higher sdLDL-C (10.9%), compared to those with low sdLDL-C and discordantly higher
LDL-C (7.9%). However, similar analyses using non-HDL-C, the recommended lipid metric for CVD
risk assessment by most guidelines, was not reported.
Mora et al. (2014) [11] published a study based on the Women’s Health Study, a large prospective
population-based study. Participants were women aged >45 years and were free of cardiovascular
disease at admission. This study included 27,533 participants, with a mean follow-up time of 17.2 years.
During the follow-up period 1070 CVD-events occurred. The aim of this study was to determine
the prevalence of and long-term prognosis for cardiovascular events in participants with discordant
levels of LDL-C compared with LDL-P, non-HDL-C (NHDL-C), and apoB. LDL-P was determined
using NMR. Among the women with below-median LDL-C and discordantly high NHDL-C, apoB,
and LDL-P above the median, LDL-C underestimated the risk of cardiovascular events by 30–50%
(Figure 2), but, importantly, LDL-P was not found to be superior to NHDH-C or apoB. This is in line
with a 2009 study based on the same material [11].
Parish et al. (2012) [42] published a study based on the Heart Protection Study, a randomized
controlled trial that included 20536 participants, between the ages of 40 and 80 years, who received
either 40mg of simvastatin or a placebo once daily, with a mean follow up time of 5.3 years. Using
baseline blood samples, they evaluated the associations between a variety of lipoprotein metrics,
including LDL subfractions, determined by NMR, and cardiovascular outcomes. Primary endpoints
(occlusive coronary events, revascularization, other cardiac events, and stroke) were equally strongly
associated with LDL-C, apoB, NHDL-C, and LDL-P (Figure 2).
Overall, these studies seem to support an independent association between small LDL
subfractions, or LDL-P, and hard cardiovascular outcomes, but inconsistencies between the studies
should be noted and definitive evidence that LDL subfractions add predictive value to the established
standard risk markers is lacking.
6. LDL Subfractions and PCSK9 Inhibitors
PCSK9 inhibitors reduce serum levels of LDL by blocking the degradation of the LDL receptor
(LDLR) in hepatocytes and, thus, increasing the number of LDLRs on the cell surface, increasing LDL
clearance in the liver [43]. Three major randomized trials have shown that PCSK9 inhibitors reduce
the risk of cardiovascular events (FOURIER [44] and SPIRE-2 [45]) and all-cause mortality (ODYSSEY
Outcomes—presented at ACC 2018, not published) in high-risk patients. The drugs are well tolerated
and adverse effects are minimal, including no indications of adverse neurocognitive effects in patients
with very low LDL-C levels. However, long-term data are needed [46].
Based on these results, PCSK9 inhibitors have now been included in CVD prevention
guidelines [13,14] as a lipid lowering therapy to be considered for patients at very high risk of
CVD. Very high risk patients are usually defined as patients with familial hypercholesterolemia (FH),
in secondary prevention for patients with high residual risk after statin therapy, or patients who do
not tolerate appropriate doses of statins. Currently, individuals without FH in primary prevention do
not fulfil cost-effectiveness criteria due to the high costs of these new drugs [47,48].
Pre-clinical trials have reported an independent association between plasma levels of PCSK9 and
small LDL subfractions in patients with established CVD [49,50] and abdominally obese dyslipidemic
men [51], but not in healthy subjects [52], suggesting that plasma levels of PCSK9 could be related to
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the metabolism of small LDL subfractions in patients at risk of CVD. An impaired affinity of sdLDL to
LDLR [33] could suggest that PCSK9 inhibitors are less efficient in reducing the small LDL particles
compared to the larger LDL particles. As the PCSK9 inhibitors have just recently been introduced,
a limited number of clinical studies evaluating the effects of PCSK9 inhibitors on LDL subfractions
have been published. Baruch et al. published a study on the effects of RG7652, a novel PCSK9 inhibitor,
on LDL subfractions evaluated by NMR in a randomized trial including 248 patients [53]. In this trial,
they demonstrated reductions in LDL-C of up to 52.4%, which is comparable to other PCSK9 inhibitors
that are already available. Both the small and large LDL-particles were reduced significantly at the
optimal dose of RG7652, but the median percentage change was lower for the smaller LDL-particles
compared to the larger particles (−43% vs. −81% from baseline), and 11 of the 45 patients showed an
increase in the small LDL particles at the end of the study. Two smaller studies on the PCSK9 inhibitors,
alirocumab and evolocumab, also reported a proportionally larger reduction in the large LDL particles
compared to the small LDL particles, but significant reductions nonetheless [54,55]. In a pilot study
of three patients with FH, who converted from lipid apheresis to evolocumab, our group reported
reductions of all LDL subfractions [56]. For comparison, studies evaluating the effects of statins on
LDL subfractions are more discordant, with no changes [57,58], significant decreases [59–62], and also
slight increases [63] of LDL subfraction metrics being reported.
To summarize, PCSK9 inhibitors seem to be effective at lowering all LDL subfractions, but with
a trend towards a more efficient lowering of the larger LDL subfractions.
7. Conclusions
PCKS9 inhibitors have been proven to reduce the risk of cardiovascular events and all-cause
mortality in patients at high risk of CVD, with minimal adverse effects reported in short-term trials.
With these new drugs, physicians now have another powerful tool to aggressively target and lower
LDL-C, a causal agent in the development of atherosclerotic cardiovascular disease. As these drugs
come at a considerable cost, and with long-term adverse effects unknown, it is important to critically
evaluate when patients should be considered for PCKS9 inhibitors. Current CVD prevention guidelines
have stated that patients at very high risk of CVD should be considered for PCSK9 inhibitors.
It has been proposed that measuring LDL subfractions, specifically small dense LDL or LDL-P,
could improve CVD risk assessment and identify patients at high risk of CVD. In-vitro studies have
indicated that small, dense LDLs are more atherogenic than larger LDL particles. Several methods
for the determination of LDL subfractions and LDL-P are used in the published literature, however,
several factors limit their availability. Furthermore, a lack of standardization makes comparison
between these methods challenging. As these methods separate LDL particles based on completely
different physicochemical properties, it is not possible to determine whether the different methods are
measuring the same subfractions.
Longitudinal population studies indicate that increased levels of small dense LDL, or increased
LDL-P, are independently associated with an increased risk of cardiovascular disease. However,
definitive evidence that LDL subfractions, or LDL-P, add predictive value to the standard risk markers,
which are readily available at most clinical laboratories, is lacking. No studies have shown that
these measurements improve clinical outcomes. Based on the 2009 American Heart Association
(AHA) framework for novel risk markers [64], a new risk marker should predict future outcomes in
prospective studies, add predictive information to established risk markers, improve clinical outcomes,
and be determined as cost-effective when compared to established risk markers. This framework sets
a high standard for novel risk markers and should be considered a guideline. However, evidence that
the novel risk marker adds predictive value to an established marker is of critical importance.
Despite indications that PCSK9 inhibitors are effective at lowering sdLDL and LDL-P, important
pieces of evidence proving that LDL subfractions and LDL-P yield clinically useful information is
lacking, and these measurements are not recommended in the evaluation of whether to initiate PCKS9
inhibitors in patients at risk of CVD.
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In order to use analysis of LDL subfractions in clinical risk evaluation, standardization of methods
and a general agreement regarding which fractions to include in such an assessment is required.
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Abstract: Dyslipidemia is a major risk factor for cardiovascular disease (CVD), which is the leading
cause of morbidity and mortality in type 2 diabetes (T2DM). Statins have played a crucial role in its
management, but residual risk remains since many patients cannot achieve their desired low-density
lipoprotein cholesterol (LDL-C) level and up to 20% of patients are statin-intolerant, experiencing
adverse events perceived to be caused by statins, most commonly muscle symptoms. Recently,
great advances have been made in nonstatin treatment with ezetimibe, a cholesterol absorption
inhibitor, and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs),
all showing a proven benefit with an excellent safety profile in cardiovascular outcome trials.
This review summarizes the key aspects and the evolving role of these agents in the management
of dyslipidemia in patients with T2DM, along with a brief introduction of novel drugs currently
in development.
Keywords: dyslipidemia; type 2 diabetes; PCSK9; nonstatin
1. Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals
with type 2 diabetes (T2DM) [1,2]. In the Finnish study, which showed that T2DM is a coronary
heart disease (CHD) equivalent, type 2 diabetic patients without prior myocardial infarction (MI) and
nondiabetic patients with prior MI had a similar incidence of MI and risk of CHD death. Furthermore,
when less stringent criteria for prior CHD (MI, angina pectoris, or ischemic electrocardiogram changes)
were used, T2DM carried a larger risk than prior CHD [3,4]. Diabetic dyslipidemia, characterized by
increased triglyceride (TG) level and decreased high-density lipoprotein cholesterol (HDL-C) level,
is a major risk factor for CVD. Although low-density lipoprotein cholesterol (LDL-C) level is typically
normal, small dense LDL particles, which are more atherogenic since they are more likely to undergo
glycation and oxidation, are more prevalent in T2DM [5].
CARDS (Collaborative Atorvastatin Diabetes Study) [6] and the Heart Protection Study [7]
have shown the efficacy of statins in diabetic patients, and in the Cholesterol Treatment Trialists’
meta-analysis of diabetic patients, statins reduced major vascular events by 21% and all-cause mortality
by 9% for each 38.7 mg/dL (1.0 mmol/L) reduction in LDL-C [8]. Major guidelines recommend statins
for the treatment of dyslipidemia in T2DM [2,9–12], but even with high-dose statins, 12.7% and 40.4%
of patients do not achieve LDL-C levels below 100 mg/dL and 70 mg/dL, respectively [13]. Moreover,
in clinical practice, statin-associated muscle symptoms occur in up to 20% of patients and contribute
to their discontinuation [14]. New treatment strategies are needed, and this review focuses on recent
advances in nonstatin treatment, with special attention to proprotein convertase subtilisin/kexin type
9 (PCSK9) monoclonal antibodies (mAbs).
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2. Search Strategy
We searched PubMed, ClinicalTrials.gov, and other sources for articles published in English
between 1 January 2000 and 1 April 2018, using the search terms “dyslipidemia”, “type 2 diabetes”,
“PCSK9”, “evolocumab”, and “alirocumab”. We also searched the reference lists of articles identified
by this search strategy along with manually selected articles known to the authors.
3. Nonstatin Lipid-Lowering Therapies
3.1. Ezetimibe
Ezetimibe reduces cholesterol absorption by inhibiting Niemann-Pick C1-Like 1 (NPC1L1) protein
in the small intestine and hepatocytes [15,16]. In the IMPROVE-IT (Improved Reduction of outcomes:
Vytorin Efficacy International Trial) [17], the first trial to show an improvement in cardiovascular
(CV) outcomes with the addition of a nonstatin drug to a statin, 18,144 patients who had been
hospitalized for an acute coronary syndrome (ACS) within the preceding 10 days were randomized to
simvastatin–ezetimibe combination therapy or simvastatin monotherapy. With a median follow-up
of 6 years, the addition of ezetimibe to simvastatin reduced LDL-C by 16 mg/dL and resulted in
a 6.4% reduction (32.7% vs. 34.7%; hazard ratio (HR) 0.936; 95% confidence interval (CI) 0.89–0.99;
p = 0.016) in the primary endpoint, which was a composite of CV death, MI, unstable angina requiring
hospitalization, coronary revascularization, or stroke, compared to simvastatin monotherapy (Table 1).
There were no differences in adverse events, including muscle-related events.
Table 1. Cardiovascular outcome trials of nonstatin drugs.
Variable IMPROVE-IT [17] FOURIER [18] ODYSSEY Outcomes [19]
No. of patients 18,144 27,564 18,924
No. of patients with
diabetes 4933 (27%) 11,031 (40%) [20] 5444 (29%)
Mean age (years) 64 63 58
Clinical
characteristics ACS within 10 days
ASCVD and LDL-C ≥70 mg/dL or
non-HDL-C ≥100 mg/dL on statin
ACS within 12 months; LDL-C ≥70
mg/dL or non-HDL-C ≥100 mg/dL
or ApoB ≥80 mg/dL on
high-intensity statin
Intervention
Simvastatin 40 mg and
ezetimibe 10 mg vs.
simvastatin 40 mg
Evolocumab 140 mg q 2w or 420 mg q 4w
vs. placebo
Alirocumab 75–150 mg q 2w vs.
placebo
Primary endpoint
CV death, MI, stroke,
hospitalization for UA,
coronary revascularization
CV death, MI, stroke, hospitalization for
UA, coronary revascularization
CHD death, MI, ischemic stroke,
hospitalization for UA
Median f/u (years) 6 2.2 2.8
Achieved LDL-C
(mg/dL) 53.7 vs. 69.5 30 vs. 92 53.3 vs. 101.4
Primary endpoint 32.7% vs. 34.7%; HR 0.936(95% CI 0.89–0.99); p = 0.016
9.8% vs. 11.3%; HR 0.85 (95% CI 0.79–0.92);
p < 0.001
9.5% vs. 11.1%; HR 0.85 (95% CI
0.78–0.93); p = 0.0003
3-point MACE (CV
death, MI, stroke)
22.2% vs. 20.4%; HR 0.90
(95% CI 0.84–0.96); p = 0.003
5.9% vs. 7.4%; HR 0.80 (95% CI 0.73–0.88);
p<0.001
10.3% vs. 11.9%; HR 0.86 (95% CI
0.79–0.93); p = 0.0003 *
CV death 6.8% vs. 6.9%; HR 1.00 (95%CI 0.89–1.13); p = 1.00
1.8% vs. 1.7%; HR 1.05 (95% CI 0.88–1.25);
p = 0.62
2.5% vs. 2.9%; HR 0.88 (95% CI
0.74–1.05); p = 0.15
All-cause death 15.3% vs. 15.4%; HR 0.99(95% CI 0.91–1.07); p = 0.78
3.2% vs. 3.1%; HR 1.04 (95% CI 0.91–1.19);
p = 0.54
3.5% vs. 4.1%; HR 0.85 (95% CI
0.73–0.98); p = 0.026
Adverse events Similar safety in both groups Injection-site reactions: 2.1% vs. 1.6%Neutralizing antibodies: 0% in both groups
Injection site reactions: 3.8% vs. 2.1%
Neutralizing antibodies: 0.4% vs. 0.1%
ACS = acute coronary syndrome; AMI = acute myocardial infarction; ApoB = apolipoprotein B;
ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CI = confidence interval;
CV = cardiovascular; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects
with Elevated Risk; HR = hazard ratio; HDL-C = high-density lipoprotein cholesterol; IMPROVE-IT = Improved
Reduction of outcomes: Vytorin Efficacy International Trial; LDL-C = low-density lipoprotein cholesterol;
MACE = major adverse cardiovascular events; MI = myocardial infarction; UA = unstable angina; * 3-point MACE
for all-cause death, MI, stroke.
Of the study subjects, 4933 (27%) had diabetes at baseline, and compared to patients without
diabetes, ezetimibe was associated with an enhanced benefit ((HR 0.86; 95% CI 0.78–0.94 for patients
with diabetes) vs. (HR 0.98; 95% CI 0.92–1.04 for patients without diabetes); p value = 0.023 for
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interaction) in the primary endpoint with similar safety outcomes [21]. In addition, in a prespecified
analysis which compared outcomes stratified by achieved LDL-C level at 1 month, the adjusted HRs for
the primary endpoint favored lower achieved LDL-C groups (HRs of 1.0, 0.82, 0.80, and 0.79 for LDL-C
>70, 50–69, 30–49, and <30 mg/dL, respectively; p for trend <0.001) without an increase in adverse
events [22]. These results suggest the benefit of the addition of ezetimibe in diabetic patients after an
ACS and perhaps also in patients with stable clinical atherosclerotic cardiovascular disease (ASCVD).
3.2. PCSK9 Inhibitors
In 2003, gain-of-function mutations in PCSK9 were reported as a cause of hypercholesterolemia [23].
Soon after, low LDL-C in individuals with loss-of-function mutations in PCSK9 was reported [24], and a
moderate lifelong reduction in LDL-C (15–28%) resulted in a substantial reduction in the incidence of
CHD by 47–88% [25]. Furthermore, individuals with no circulating PCSK9 and very low LDL-C due to
compound heterozygous loss-of-function mutations in PCSK9 were apparently healthy [26], making
PCSK9 inhibition a very attractive target for LDL-C-lowering therapy.
Plasma LDL-C binds to LDL receptors expressed on the surface of hepatocytes and is internalized
by endocytosis [27]. LDL receptors are usually recycled to the cell surface, but when PCSK9 binds with
LDL receptors, LDL receptors are delivered to lysosomes for degradation, resulting in lower expression
of LDL receptors and an increase in LDL-C [28]. Therapeutic approaches targeting extracellular PCSK9
(e.g., mAbs) and intracellular PCSK9 (e.g., small interfering RNAs (siRNAs)) are currently under
investigation, but mAbs have been the most successful strategy thus far [29].
3.2.1. Monoclonal Antibodies
Evolocumab and alirocumab, two subcutaneous agents currently available on the market,
have been studied in numerous populations, including familial hypercholesterolemia, diabetes,
and statin intolerance, as monotherapy and in combination with statins. In a meta-analysis of
phase 2 and 3 studies, treatment with PCSK9 mAbs reduced LDL-C by 55% [30]. Moreover,
OSLER (Open-Label Study of Long-Term Evaluation against LDL Cholesterol) 1 and 2 [31] and
ODYSSEY LONG TERM (Long-term Safety and Tolerability of Alirocumab in High Cardiovascular
Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid-Modifying
Therapy) [32], which were long-term studies of 1 to 1.5 years, have shown a significant reduction in
CV events of roughly 50%. However, the number of CV events was small, and confirmation in trials
adequately powered to examine CV outcomes are eagerly awaited. The results of FOURIER (Further
Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) [18] and
ODYSSEY Outcomes [19] have been recently reported and are discussed below.
3.2.2. Cardiovascular Outcomes Trial: FOURIER
FOURIER [18] included 27,564 patients with ASCVD and LDL-C ≥ 70 mg/dL who were receiving
statin therapy. Patients were randomly assigned to evolocumab (140 mg every 2 weeks or 420 mg
monthly) or placebo, and at 48 weeks, evolocumab reduced LDL-C by 59% compared to placebo,
from a median baseline value of 92 mg/dL to 30 mg/dL. With a median follow-up of 2.2 years,
evolocumab significantly reduced the primary endpoint, which was a composite of CV death, MI,
stroke, hospitalization for unstable angina, or coronary revascularization, by 15% (9.8% vs. 11.3%;
HR 0.85; 95% CI 0.79–0.92; p < 0.001), and the key secondary endpoint, which was a composite of CV
death, MI, or stroke, by 20% (5.9% vs. 7.4%; HR 0.80; 95% CI 0.73–0.88; p < 0.001) (Table 1). Although
the magnitude of the risk reduction in the primary and key secondary endpoints appeared to grow
over time, there were no significant differences in CV death (HR 1.05; 95% CI 0.88–1.25) and all-cause
mortality (HR 1.04; 95% CI 0.91–1.19).
Diabetes was present at baseline in 11,031 (40%) patients, and in a prespecified secondary
analysis [20], similar efficacy in the primary and key secondary endpoints was observed in patients
with and without diabetes. However, since patients with diabetes had a higher baseline risk, they
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seemed to have a greater absolute risk reduction in the primary endpoint over 3 years ((2.7%; number
needed to treat 37) vs. (1.6%; number needed to treat 62); p = 0.60 for interaction). This benefit was
driven largely by a greater absolute risk reduction in coronary revascularization, and there was no
difference in the absolute risk reduction for the key secondary endpoint.
3.2.3. Cardiovascular Outcomes Trial: ODYSSEY Outcomes
ODYSSEY Outcomes [19] included 18,924 patients who had been hospitalized for an ACS 1 to
12 months prior to randomization. After a run-in period of 2 to 16 weeks on high-intensity statins,
patients with LDL-C ≥ 70 mg/dL, non-HDL-C ≥ 100 mg/dL, or apolipoprotein B ≥ 80 mg/dL
were randomized to alirocumab (75 mg every 2 weeks) or placebo. A target LDL-C level of
25 to 50 mg/dL was specified, with up-titration of alirocumab to 150 mg every 2 weeks in
patients with LDL-C ≥ 50 mg/dL and a blinded switch to placebo in patients who consistently had
LDL-C < 15 mg/dL.
In the on-treatment analysis, which excluded LDL-C values after premature treatment
discontinuation or blinded switch to placebo, alirocumab reduced LDL-C by 61% from a mean
LDL-C of 96.4 mg/dL to 42.3 mg/dL at 1 year, and by 54.7% from a mean LDL-C of 101.4 mg/dL to
53.3 mg/dL at 4 years. With a median follow-up of 2.8 years, alirocumab significantly reduced the
primary endpoint, which was a composite of CHD death, MI, ischemic stroke, or unstable angina
requiring hospitalization, by 15% (9.5% vs. 11.1%; HR 0.85; 95% CI 0.78–0.93; p = 0.0003), and the
secondary composite endpoint of all-cause death, MI, or ischemic stroke by 14% (10.3% vs. 11.9%;
HR 0.86; 95% CI 0.79–0.93; p = 0.0003) (Table 1). Although all-cause death was significantly lower with
alirocumab, there were no significant differences in CHD death and CV death.
In a prespecified secondary analysis stratified by baseline LDL-C, patients with
LDL-C ≥ 100 mg/dL appeared to gain the most benefit, with reductions in the primary and
secondary endpoints, although the p value for interaction was not significant. Roughly 30% of patients
had diabetes and considering that diabetes is associated with higher mortality after an ACS [33], a
greater absolute risk reduction might have been seen in this population, and we await the results of
further analysis.
3.2.4. Safety of Monoclonal Antibodies and Low LDL-C
Cholesterol is an essential component of all cell membranes and is critical to the maintenance of
normal cell functions, such as gonadal hormones, adrenal function, and brain function. Therefore,
theoretical concerns have been raised regarding the extremely low level of LDL-C achieved with
PCSK9 mAbs [34]. Both evolocumab and alirocumab were safe and well tolerated in FOURIER [18]
and ODYSSEY Outcomes [19], although longer follow-up periods are needed since both trials had
a relatively short follow-up period of less than 3 years. A prespecified secondary analysis of
FOURIER [35] showed a highly significant monotonic relationship between achieved LDL-C and
major CV outcomes, without a significant association with safety outcomes, which is in accordance
with the results of a secondary analysis from IMPROVE-IT [22]. Currently, evolocumab has been
studied for up to 4 years in the open-label OSLER-1 extension study and has shown a good safety
profile [36]. An open-label extension study of FOURIER is ongoing, which will investigate 6600
subjects for 5 years and will provide more information regarding its long-term safety (NCT03080935,
NCT02867813). Key adverse events are briefly discussed below.
3.2.5. Muscle-Related Events
In FOURIER [18], rates of muscle-related events were similar between evolocumab and placebo
(5.0% vs. 4.8%, respectively). Details of ODYSSEY Outcomes [19] have not been reported yet, but in
ODYSSEY LONG TERM [32], alirocumab had a higher rate of myalgia compared to placebo (5.4% vs.
2.9%, respectively).
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3.2.6. Injection Site Reactions
In FOURIER [18] and ODYSSEY Outcomes [19], injection site reactions were rare, but were
significantly more frequent with both evolocumab (2.1% vs. 1.6%) and alirocumab (3.8% vs. 2.1%)
compared to placebo.
3.2.7. Antidrug Antibodies
The development of bococizumab, a humanized mAb with approximately 3% of the murine
sequence remaining, was discontinued in part due to the development of a high rate of antidrug
antibodies which diminished the magnitude and durability of LDL-C reduction [37]. In contrast,
evolocumab and alirocumab are fully humanized mAbs, and in FOURIER [18], only 0.3% of patients
developed new antidrug antibodies, and development of neutralizing antibodies did not occur in any
patient. In ODYSSEY Outcomes [19], neutralizing antibodies developed in 0.4% and 0.1% of patients
in the alirocumab and placebo group, respectively, and slight attenuation of LDL-C lowering over time
was observed in the trial. Further analyses are needed to elucidate whether neutralizing antibodies had
a negative effect or if it was mainly due to the trial design with a specified down-titration algorithm
at low LDL-C levels. In a previous report of 4747 patients from 10 trials of alirocumab, neutralizing
antibodies were observed in 1.3% of patients, but reductions in LDL-C were maintained over time
regardless of neutralizing antibody status [38].
3.2.8. Neurocognitive Events
In FOURIER [18] and ODYSSEY Outcomes [19], there were no significant differences in
neurocognitive events for both evolocumab (1.6% vs. 1.5%) and alirocumab (1.5% vs. 1.8%) compared
to placebo. Cognitive function was prospectively assessed in a subgroup of patients from FOURIER
in EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High
Cardiovascular Risk Subjects) [39] using the Cambridge Neuropsychological Test Automated Battery
(CANTAB), a computerized cognitive assessment tool that uses touch-screen neuropsychological tests
of cognition that are specifically designed to assess central nervous system disorders and cognitive
function. A total of 1204 patients were followed for a median of 19 months, and there were no significant
differences in the CANTAB score between patients who received evolocumab and placebo. The ongoing
5-year extension of FOURIER includes CANTAB assessments in approximately 500 patients who had
also participated in EBBINGHAUS and will provide longer-term data regarding cognition. A clinical
trial of alirocumab is also ongoing, with prospective CANTAB assessments in 2200 patients with a
follow-up period of 2 years (NCT02957682). Lastly, a recently reported mendelian randomization
study provides reassurance, as genetic variants in PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme
A reductase (HMGCR, the target of statins) showed no causal effects of low LDL-C on the risk of
Alzheimer’s disease, Parkinson’s disease, and dementia [40].
3.2.9. New-Onset Diabetes
Meta-analyses of randomized trials have shown a dose-dependent relationship between statins
and risk of incident diabetes, with a higher risk in patients receiving intensive-dose therapy compared
with moderate-dose therapy (OR 1.12; 95% CI 1.04–1.22) [41,42]. Mendelian randomization studies
with genetic variants in PCSK9 have also shown an increased risk of diabetes [43,44], and whether
PCSK9 mAbs carry a risk of development of diabetes has been a matter of concern. In a prespecified
secondary analysis of FOURIER [20], evolocumab did not increase the risk of new-onset diabetes in
patients without diabetes at baseline (HR 1.05; 95% CI 0.94–1.17), including in those with prediabetes
(HR 1.00; 95% CI 0.89–1.13). Levels of HbA1c and fasting plasma glucose were similar between the
evolocumab and placebo groups over time in patients with diabetes, prediabetes, or normoglycemia.
In ODYSSEY Outcomes [19], alirocumab did not increase the risk of new-onset diabetes in patients
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without diabetes at baseline (9.6% vs. 10.1%) and did not have an adverse effect of worsening diabetes
or diabetic complications in patients with diabetes at baseline (18.8% vs. 21.2%).
3.2.10. Cost-Effectiveness
The efficacy and safety of evolocumab and alirocumab in FOURIER [18] and ODYSSEY
Outcomes [19] are very promising, but with a hefty price tag of $14,000 per year in the United
States. Three cost-effectiveness analyses [45–47] incorporating data from FOURIER have been reported,
with an incremental cost-effectiveness ratio (ICER) of $268,600 to $450,000 per quality-adjusted life-year
(QALY), and a 60% to 70% reduction from current prices would be needed to achieve a societally
acceptable ICER of $100,000 per QALY [48].
3.2.11. Intracellular PCSK9 Inhibitors: Inclisiran
Inclisiran is a long-acting, subcutaneously delivered siRNA targeting PCSK9 messenger RNA
(mRNA) [49]. It is attached to an N-acetylgalactosamine moiety, which facilitates selective uptake into
liver cells via the asialoglycoprotein receptor [50]. After binding intracellularly to the RNA-induced
silencing complex (RISC), it specifically cleaves mRNA encoding PCSK9 [49].
In ORION-1 [51], a phase 2 study of inclisiran, 501 patients at high risk for CVD, of which 118
(24%) patients had diabetes at baseline, with elevated LDL-C despite maximum tolerated dose of
statins were randomized to receive a single dose of placebo or 200, 300, or 500 mg inclisiran or two
doses (on days 1 and 90) of placebo or 100, 200, or 300 mg inclisiran. Inclisiran reduced PCSK9 and
LDL-C levels in a dose-dependent manner, and at 6 months, LDL-C reductions of 27.9% to 41.9%
after a single dose and 35.5% to 52.6% after two doses (p < 0.001 for all comparisons vs. placebo)
were observed. The two-dose 300 mg inclisiran regimen produced the greatest reduction in LDL-C
with a mean reduction of 64.2 mg/dL from baseline, with 48% and 66% of patients achieving LDL-C
<50 mg/dL and <70 mg/dL, respectively. There seemed to be no adverse events related to inclisiran,
but 5% of patients who received inclisiran experienced injection-site reactions whereas no injection-site
reactions occurred in patients assigned to placebo.
Whether there is a clinically meaningful difference in intracellular and extracellular PCSK9
inhibition remains unknown. However, inclisiran has the advantage of a twice-yearly injection and a
lower manufacturing cost when compared with PCSK9 mAbs, which require an injection every 2 to
4 weeks with a substantial cost burden [52]. ORION-10 (NCT03399370) and ORION-11 (NCT03400800),
phase 3 studies recruiting a combined total of 3,000 patients with ASCVD and elevated LDL-C despite
maximum tolerated dose of statins, are ongoing, and ORION-4 [53], a randomized CV outcome trial of
inclisiran in 15,000 patients with stable ASCVD and LDL-C ≥ 100 mg/dL with a median follow-up of
5 years, is planned.
3.3. Bempedoic Acid
Bempedoic acid (ETC-1002) is a once-daily, orally administered prodrug that inhibits adenosine
triphosphate citrate lyase (ACL), a key enzyme upstream of HMGCR involved in the synthesis of
fatty acids and cholesterol [54,55]. It also activates 5′-adenosine monophosphate-activated protein
kinase (AMPK), reducing the activity of acetyl-CoA carboxylase (ACC) and HMGCR, the rate-limiting
enzymes of fatty acid and cholesterol synthesis, respectively [55]. The activation of AMPK also
targets phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, enzymes with a crucial role
in gluconeogenesis and liver glucose production [55] and seems to have a favorable effect on glucose
regulation in animal models [56]. In the liver, the prodrug is activated by very long-chain acyl-CoA
synthetase-1 (ASCVL1), but since skeletal muscle does not express ASCVL1, it remains in its inactive
form and can potentially avoid the myotoxicity associated with statins [54].
In phase 2 clinical trials, bempedoic acid has shown significant LDL-C reductions of up to 50%
when combined with ezetimibe [57], and in patients with type 2 diabetes [56], it was associated
with a nonsignificant reduction in fasting and postprandial glucose concentrations, along with a
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nonsignificant tendency of improved glycemic control in a 24-h continuous glucose monitoring
assessment compared to placebo. A phase 3 CV outcome trial involving 12,600 high-risk patients who
are statin intolerant is ongoing (CLEAR Outcomes; NCT02993406).
3.4. Fibrates
Fibrates are agonists of peroxisome proliferator-activated receptor alpha (PPARα), mediating
transcription factors that control lipoprotein metabolism [58]. They improve the lipid profile of
diabetic dyslipidemia by decreasing TG level and increasing HDL-C level, but recent trials have
failed to show a benefit in outcomes, both with monotherapy [59] and in addition to a statin [60].
In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial [60], the addition
of fenofibrate to simvastatin in high-risk patients with T2DM did not reduce the primary endpoint,
which was a composite of MI, stroke, or CV death, with a mean follow-up of 4.7 years. However,
in a prespecified subgroup analysis, a possible benefit for patients with both a high baseline TG
level ≥ 204 mg/dL and a low baseline level of HDL-C ≤ 34 mg/dL was suggested, with similar
post hoc subgroup analysis in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes)
study [61]. PROMINENT (Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides
IN patiENts with diabeTes; NCT03071692), a CV outcome trial of pemafibrate is currently underway,
and will investigate 10,000 patients with T2DM who have TG level ≥ 200 mg/dL and HDL-C
level ≤ 40 mg/dL despite concomitant statin therapy.
3.5. Omega 3 Fatty Acids
Omega 3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) decrease
TG level, but they have produced even more inconsistent results than fibrates [62]. We await the
results of two ongoing CV outcome trials, REDUCE-IT (Reduction of Cardiovascular Events with
Icosapent Ethyl-Intervention Trial; NCT01492361) and STRENGTH (A Long-Term Outcomes Study
to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With
Hypertriglyceridemia; NCT02104817), which will evaluate the effect of omega 3 fatty acids on top of
statins in high-risk patients with mixed dyslipidemia.
4. Therapeutic Strategies for Dyslipidemia in Patients with Type 2 Diabetes
Some guidelines recommend an LDL-C treatment target, while others recommend a specific
statin intensity without an LDL-C target (Table 2) [2,9–12]. However, they all agree on statins as the
first-line treatment, and problems arise when patients cannot achieve their target LDL-C level or
are statin-intolerant. First and foremost, accurate identification of true statin intolerance is of vital
importance, since many patients are able to tolerate statins when rechallenged. Statin-associated muscle
symptoms are usually not of pharmacological origin, but rather a consequence of patient perceptions
that statins can cause muscle symptoms, combined with the high background prevalence of muscle
symptoms in middle-aged and elderly patients [14]. In GAUSS-3 (Goal Achievement After Utilizing
an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3) [63], 511 patients intolerant to multiple statins
were rechallenged in a double-blinded manner with one half of the patients randomized to atorvastatin
20 mg and the other half randomized to placebo for the first 10 weeks, with subsequent crossover to
the alternate treatment group. During this rechallenge phase, 26.5% of patients experienced muscle
symptoms with placebo but not with atorvastatin, supporting the aforementioned notion, although
true statin intolerance clearly exists in some patients as 42.6% of patients experienced muscle symptoms
with atorvastatin but not with placebo.
Ezetimibe should be used in patients who fail to achieve their target LDL-C level with statins
alone or are statin-intolerant in view of the benefits proven in IMPROVE-IT [17]. We prefer ezetimibe
over PCSK9 mAbs due to its oral administration and low cost, and PCSK9 mAbs should be reserved for
very high-risk patients with clinical ASCVD and LDL-C above their target level despite concomitant
use of statins and ezetimibe. Gemfibrozil, a type of fibrate, inhibits statin glucuronidation and
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leads to the elevation of plasma statin concentration. Therefore, it should not be combined with
statins because of an increased risk of myotoxicity [64]. In contrast, fenofibrate does not have a
significant effect on statin glucuronidation, and there was no increased risk in the ACCORD lipid trial
where fenofibrate–simvastatin combination therapy was investigated [60]. The addition of fenofibrate
may be considered in high-risk patients with elevated TG level and low HDL-C level despite statin
treatment, taking into account the suggested benefit in the subgroup analyses of ACCORD lipid [60]
and FIELD [61].
Table 2. Recommendations for treatment of dyslipidemia in patients with T2DM.























LDL-C < 70 mg/dL LDL-C < 70 mg/dL(age > 40 years) LDL-C < 100 mg/dL
If LDL-C above target, consider ezetimibe.
If LDL-C > 100 mg/dL in ASCVD (+),
also consider PCSK9 mAb. *
CHD (+) CHD (−) Nonstatin Treatment
2017 JAS [12]
LDL-C <100 mg/dL
(LDL-C <70 mg/dL in
very high-risk patients)
LDL-C < 120 mg/dL
(age 40–74 years)
If LDL-C above target, consider
combination therapy (no specific drug
indicated).
(b) Guidelines with statin intensity recommendations













If <50% LDL-C reduction, consider
ezetimibe.
If ASCVD (+), also consider PCSK9 mAb.
ASCVD (+) ASCVD (−) Nonstatin Treatment
2018 ADA [2] High-intensity statin
Moderate-intensity
statin
(age ≥ 40 years)
If LDL-C ≥ 70 mg/dL in ASCVD (+),
consider ezetimibe or PCSK9 mAb.
AACE/ACE = American Association of Clinical Endocrinologists/American College of Endocrinology;
ACC/AHA = American College of Cardiology/American Heart Association; ADA = American Diabetes
Association; ASCVD = atherosclerotic cardiovascular disease; CAD = coronary artery disease; CVD = cardiovascular
disease; ESC/EAS = European Society of Cardiology/European Atherosclerosis Society; JAS = Japan Atherosclerosis
Society; LDL-C = low-density lipoprotein cholesterol, mAb = monoclonal antibody; PCSK9 = proprotein convertase
subtilisin/kexin type 9; * LDL-C threshold, the starting value on which treatment decisions for a PCSK9 mAb are
based, which is different from the LDL-C goal, the aim of therapeutic intervention.
5. Conclusions
Statins have been and will remain the cornerstone of treatment of dyslipidemia in patients with
diabetes. However, residual risk remains, and nonstatin treatment with ezetimibe and PCSK9 mAbs
has an evolving role with proven benefits on CV outcomes. As the most potent LDL-C-lowering agent
available on the market, PCSK9 mAbs have huge expectations, but their long-term safety remains to
be established, and their prices must come down for them to be cost-effective. Inclisiran would be
a huge addition to our arsenal especially if their market price is much cheaper than PCSK9 mAbs.
The potential of bempedoic acid to avoid the myotoxicity of statins with a favorable effect on glucose
metabolism is exciting, and we eagerly await the results of CV outcome trials of fibrates and omega
3 fatty acids to further understand the role of high TG level in CVD. We have made huge progress
but much remains to be done, and further advances to improve the care of our patients should
be anticipated.
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Abstract: The role of low-density lipoproteins (LDLs) as a major risk factor for cardiovascular
disease has been demonstrated by several epidemiological studies. The molecular basis for LDLs in
atherosclerotic plaque formation and progression is not completely unraveled yet. Pharmacological
modulation of plasma LDL-C concentrations and randomized clinical trials addressing the impact of
lipid-lowering interventions on cardiovascular outcome have clearly shown that reducing plasma
LDL-C concentrations results in a significant decrease in major cardiovascular events. For many years,
statins have represented the most powerful pharmacological agents available to lower plasma LDL-C
concentrations. In clinical trials, it has been shown that the greater the reduction in plasma LDL-C
concentrations, the lower the rate of major cardiovascular events, especially in high-risk patients,
because of multiple risk factors and recurrent events. However, in a substantial number of patients,
the recommended LDL target is difficult to achieve because of different factors: genetic background
(familial hypercholesterolemia), side effects (statin intolerance), or high baseline plasma LDL-C
concentrations. In the last decade, our understanding of the molecular mechanisms involved in LDL
metabolism has progressed significantly and the key role of proprotein convertase subtilisin/kexin
type 9 (PCSK9) has emerged. This protein is an enzyme able to bind the LDL receptors (LDL-R) on
hepatocytes, favoring their degradation. Blocking PCSK9 represents an intriguing new therapeutic
approach to decrease plasma LDL-C concentrations, which in recent studies has been demonstrated
to also result in a significant reduction in major cardiovascular events.
Keywords: lipoproteins; atherosclerosis; cardiovascular risk; statin; PCSK9
1. Introduction
A strong correlation between lipid plasma levels and atherosclerotic cardiovascular disease
(ASCVD) has been clearly shown over the years [1]. Lipid deposition, mainly low-density lipoprotein
(LDL), occurs in the arterial wall of almost all vascular districts, defining the atherosclerotic process,
with focal clinical manifestations based on the organ damaged: heart (coronary artery disease), brain
(cerebrovascular disease), and/or limbs (peripheral vascular disease) [2]. Plaque complication results
in exposure of prothrombotic material to the flowing blood, leading to acute thrombus formation,
which may result in an acute medical emergency, such as acute coronary syndrome (ACS), stroke, or
related problems [3–5]. Lowering plasma LDL concentrations is highly recommended for patients
with hyperlipidemia and multiple risk factors, such as diabetes, hypertension, smoking status, chronic
kidney disease, or peripheral artery disease [6,7]. According to the current guidelines, diet and weight
loss represent the first “medical” approach [1,8]. However, pharmacological modulation of plasma
lipid concentrations is quite often necessary according to the target lipid levels.
The majority of clinical trials have shown the efficacy of statins in reducing major cardiovascular
events (MACE) in both primary and secondary prevention [9,10]. Moreover, because of their low cost,
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they are sustainable from the economic point of view. However, despite the proven efficacy, in a subset
of patients achievement of the plasma cholesterol target by statins remains an unmet clinical need
because of: (1) intolerance (defined as muscle pain and/or liver dysfunction) [11]; (2) not powerful
enough to achieve the target [12]; (3) unfavorable genetic background, (i.e., heterozygous familial
hypercholesterolemia (FH) or homozygous FH [13]).
In the last 15 years, new insight into the basic mechanisms involved in cholesterol metabolism has
been gained, and new pharmacological targets have been identified [14]. The proprotein convertase
subtilisin/kexin type 9 (PCSK9) is an example of rapid pre-clinical and clinical progression between
their discovery in 2003 and the present because of the potential the innovative therapeutic scenario
opened up [15]. This protein is a key player in the clearance of LDL particles and its inhibition seems
to be highly effective in reducing plasma LDL-C concentrations [16]. This review, starting with the role
of cholesterol in the pathogenesis of atherosclerosis in high-risk patients, will discuss the novelty of
the PCSK9 approach and the available data on the safety and effectiveness of its inhibition in reducing
plasma LDL-C concentrations.
2. Traditional Pharmacological Approaches for Dyslipidaemias: From Bench to Bedside
2.1. Atherosclerotic High-Risk Patients
Atherosclerosis is a multifactorial, chronic “inflammatory-degenerative” disease of the arterial
tree [3,17], recognizing in the atheroma its pathological substrate [18]. Conventional (hypertension,
diabetes, smoking, hyperlipidemia, age, sex) and less conventional (impaired glucose tolerance;
impaired fasting glucose, apolipoprotein B (ApoB); apolipoprotein A-I (ApoAI), triglycerides;
triglyceride-rich lipoproteins[TGRLs], small and dense LDL, oxidized-LDL, antibodies against
oxidized-LDL, Lipoprotein (a), homocysteine, high-sensitivity C-reactive protein) cardiovascular
risk factors are the main determinants for the impairment of the endothelial protective properties [19].
The resulting endothelial dysfunction [20–23] with deposition of circulating LDL-C in the arterial wall
is the initial step of the atherosclerotic process [24]. Within the subendothelial space, LDL-C become
more susceptible to oxidation due to local reactive oxygen species (ROS) production, triggering the
atherosclerotic cascade that leads to plaque formation, progression, and destabilization [2]. In each
step of this process, the role of inflammation and immunity is now well defined [3,25].
Patients with diabetes mellitus (DM) are considered at high cardiovascular risk, with a ~10-fold
increased risk in their lifetime [26–28]. Increased plaque vulnerability [29], advanced glycosylation end
products (AGEs) formation [30,31], enzyme-mediated endothelial damage [30], and a modified lipid
profile (with an increase in VLDLs and “small and dense” LDLs) [32] indicates that diabetic patients
may have accelerated atherosclerosis.
Patients with chronic kidney disease (CKD) also show an increased risk for ASCVD [33], mainly
related to a loss of renal parenchyma, which accelerates atherosclerosis [34], a chronic inflammation
status with elevated CRP levels, and reduced renal clearance of several cytokines, such as IL-1β,
IL-6, and TNF-α [35], as well as raised levels of angiotensin II and parathormone, which contribute
to increased ROS production and calcium deposition in the vessel wall, thus inducing endothelial
dysfunction [33]. Coronary plaques from CKD patients show extensive calcification and increased
presence of thrombotic events [36].
Autopsy studies have shown that fibrous plaques are more common in the femoral arteries [37,38].
Peripheral atherosclerotic disease occurs in the context of multiple disease processes that interfere with
exercise ability. Potential mechanisms include the conventional risk factors in a local setting of reduced
blood flow, altered muscle metabolism, and impaired angiogenesis, leading to limb discomfort and
functional limitation [39].
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2.2. Major Drugs Used in LDL Cholesterol-Lowering Strategies
Several randomized clinical trials have unequivocally shown that lipid-lowering therapies are
associated with MACE reduction [40–42]. Despite dietary approach, physical activity, and weight loss
being the strategies recommended first [43], many pharmacological strategies have been identified to
modulate plasma lipid levels.
(a) Statins: Inhibition of HMG-CoA reductase by statins has been the first therapeutic approach.
These drugs block the endogenous synthesis of cholesterol in the liver, resulting in a reduction of
intracellular cholesterol. This causes induction of LDL-R expression of the hepatocyte surface, which
in turn leads to enhanced clearance of LDL particles from the blood. Several trials have highlighted
an improvement in terms of cardiovascular morbidity and mortality as well as the need for coronary
artery interventions using statins [44,45]. This protective effect is of greater magnitude (a) if statin
treatment is started earlier and lasts a longer time; (b) if a high dose is given [9,10,46,47]; and/or (c)
if the percentage LDL-C reduction from baseline value is higher [48]. The PROVE IT-TIMI 22 trial
(Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction
22) demonstrated that plasma LDL-C concentrations at baseline are an important predictor of the
benefit of intensive lipid-lowering therapy [48]. Indeed, decreasing LDL-cholesterol baseline levels
is an additional benefit of intensive treatment with statins compared with moderate-dose therapy
declines. Consequently, current guidelines suggest that HMG-CoA reductase inhibitors represent the
first choice for patients with hypercholesterolemia or combined hyperlipidemia [1].
(b) Selective cholesterol absorption inhibitors: By inhibiting intestinal cholesterol and phytosterol
absorption protein (Niemann-Pick C1-Like 1, NPC1L1) present on jejunal intestinal cells, ezetimibe
decreases intestinal cholesterol absorption from dietary sources and from bile, resulting in a reduction
in hepatic cholesterol concentration and circulating LDL-C by up to 20% [14]. The IMPROVE-IT
trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) concluded that the
combination of ezetimibe plus simvastatin as compared to simvastatin alone in patients with acute
coronary syndromes resulted in a further lowering of plasma LDL-C concentrations by up to 50 mg/dL,
with an associated improvement in cardiovascular outcomes [49].
(c) Fibrates: Fibric acid derivatives, or fibrates, are agonists of α isoform of peroxisome
proliferator-activated receptor (PPAR). Activation of this receptor may result in several modifications
of the plasma lipid profile [50]. Five major effects have been characterized by the use of fibrates: (1)
Lipoprotein lipolysis induction via lipoprotein lipase activity and apoC-III inhibition; (2) increased
hepatic fatty acid uptake and reduction of hepatic triglyceride production (these two effects result
in hypotriglyceridemic action); (3) formation of LDL particles with a higher affinity for the own
receptor, thus resulting in a higher rate of LDL particles removal; (4) reduction in cholesteryl ester and
triglycerides exchange between VLDL and HDL, leading to decreased plasma levels of triglyceride-rich
lipoproteins; and (5) increase in the production of apoA-I and apoA-II in liver, thus inducing a higher
HDL production and promoting reverse cholesterol transport [51,52]. However, because of the variable
results from the clinical trials investigating the impact of fibrates on clinical outcomes, either in primary
and secondary prevention, and problems linked to safety, their role remains limited to selected patients
with diabetes, metabolic syndrome, or dyslipidemia [53–56].
A large amount of clinical trial data indicate that the central point of all lipid-lowering strategies for
high-risk patients is the percentage change from baseline rather than any predefined target. This view
is corroborated by the following findings: (1) on-treatment LDL-C plasma concentrations levels do not
predict CVD risk rates, whereas baseline LDL-C plasma concentrations do; (2) the correlation between
LDL reduction and CVD risk reduction within each study is at best curvilinear even in high-risk,
high-cholesterol populations where the average on-treatment LDL is still significantly distant from the
predefined target of 100 mg/dL; (3) despite the same percentage of LDL reduction, more benefits have
been reported in subjects with higher baseline LDL (and whose on-treatment LDL stays higher than
100 mg/dL). Despite the achieved LDL-C goal, in very high-risk patients recurrent events might occur.
By taking into account the linear correlation between LDL-C level reduction and the risk of fatal or
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nonfatal MACE, a further percentage variation from their baseline (even if it is low) might result in
additional benefits [57]. PCSK9 inhibition by monoclonal antibodies opens up a new way to achieve
this goal.
3. PCSK9 Inhibition: A Route to Very Low LDL-C Plasma Concentrations
Because of a residual cardiovascular risk in patients not at the target LDL level or with a percentage
variation from baseline still low, researchers are still looking for the best pharmacological strategy.
The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) has created a new frontier
for better management of dyslipidemia. Indeed, in 2003 Abifadel et al., studying gene mutations
responsible for familial hypercholesterolemia (FH), found that mutations in the PCSK9 gene cause
dominant hypercholesterolemia in pedigree analysis. Interestingly, a gain of function (GOF) due to a
missense mutation in this gene was the cause of the disease [58]. To date, three gene mutations are
known to cause FH: (1) the LDL receptor itself (FH1); (2) apolipoprotein (apo) B (FH2), a ligand of LDL
receptors; and (3) a GOF mutation in PCSK9 (FH3).
A better understanding of the PCSK9 pathway showed that this molecule promotes the degradation
of LDL receptors by forming an enzyme–substrate complex, mainly in the liver. The cell- surface complex
LDL-R/LDL is transported to the endosomes via endocytosis, where LDLs are released in acid conditions.
Within the endosome, LDL is degraded to amino acids and cholesterol while LDL-R is transported back
to the cell surface, but, if bound to PCSK9, LDL-R will be degraded too (Figure 1). Therefore, PCSK9
inhibition may be an effective strategy to promote LDL-R recycling, thus reducing circulating LDL
particles (Figure 1). The rate of plasma LDL-C decrease is approximately 45–60%, whether used alone or
in combination with a statin. Addition of an anti-PCSK9 antibody to standard therapy—with statin alone,
or statin combined with Ezetimibe—resulted in a further reduction of plasma LDL-C concentrations (up
to 60%) and a halved cardiovascular event rate compared to the placebo [59].
Evolocumab and Alirocumab are “fully” humanized anti-PCSK9 antibodies, while Bococizumab
is a humanized monoclonal antibody. These three monoclonal antibodies are currently under
investigation in extensive clinical programs and trials, namely PROFICIO, ODYSSEY, and SPIRE.
The latest was discontinued in November 2016.
Figure 1. Schematic view of PCSK9 activity and effects of its inhibition.
As reported above, the PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes
Following Inhibition of PCSK9 in Different Populations) is the development program for Evolocumab,
a monoclonal antibody already approved by the FDA and EMA. Several trials of this program have
already reported efficacy (with a mean of LDL-C reduction up to 57%), safety, and durable effects
in different populations [14,60,61], even patients affected by LDL receptor abnormalities such as
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homozygous or heterozygous Familial Hypercholesterolemia (FH) [62,63]. The first direct effect of
PCSK9 inhibition by evolocumab on atherosclerotic plaque comes from the GLAGOV study, published
in 2016 [64]. Coronary atherosclerotic lesions have been evaluated by intravascular ultrasound in
patients receiving evolocumab or placebo on top of statin therapy. Among patients with angiographic
evidence of coronary artery disease and on chronic statin therapy, the PCSK9 inhibitor evolocumab
resulted in a greater change in atheroma volume (−0.95% vs. +0.05% of the placebo group) and a
greater proportion of patients with plaque regression with a mean plasma LDL-C concentrations in
the active drug group of 36.6 mg/dL [64]. Moreover, the latest results available from the FOURIER
study, a large-scale outcome study in 27,564 ASCVD patients on statin therapy presented in 2017,
showed that, with the addition of evolocumab, the mean plasma LDL-C concentrations dropped to
30 mg/dL. In addition, in a median follow-up period of 2.2 years, there was a decrease in the rate of
the composite primary endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization
due to unstable angina, and coronary artery revascularization (percutaneous coronary intervention,
coronary artery bypass graft) of 15% compared with the placebo [65].
Another big program is the ODYSSEY trials testing Alirocumab. As for evolocumab, several data
from this program have already been published, showing the power and safety of this approach in
reducing LDL-C plasma concentrations by up to 47% in patients at high risk [14,60,66]. The latest
results from the ODYSSEY Outcomes trial, presented at the American College of Cardiology in 2018,
indicate that treatment with alirocumab reduced cardiovascular outcomes and all-cause deaths by 15%
in a group of high-risk patients. These data reinforce the previous data from the FOURIER trial and
expand them because of a longer outcome and a higher-risk population. A mean of 53.3 mg/dL of
LDL-C plasma concentration was achieved in the alirocumab group, with a percentage variation of
54.7. The benefits were more marked in those patients with the highest LDL cholesterol at baseline.
In the pre-specified post hoc analysis by LDL-C level at baseline, patients with an LDL-C ≥100 mg/dL
experienced reductions in all endpoints. In the alirocumab group a 24% reduction in MACE was
reported with an absolute risk reduction (ARR) of 3.4%. In detail, CHD death was reduced by 28%
(ARR 0.9%), CV death by 31% (ARR 1.3%), and all-cause death by 28% (ARR 1.7%).
The FOURIER and the ODYSSEY Outcomes trials consistently show benefits from PCSK9
inhibitors, not only in terms of preventing nonfatal events such as heart attacks but in actually
preserving life. Thus, the future is now.
A major warning raised by some recent data exploring the impact of PCSK9 inhibitors in
cardiovascular outcome, was the possible higher rate of neurocognitive adverse events [61]. However,
more recent analysis seems to not confirm this correlation. In two pre-specified analyses of the FOURIER
study, despite slightly more injection-site reactions in the evolocumab arm, the clinical efficacy and
safety of the PCSK9 therapy have been confirmed [67], with no difference between the groups especially
regarding cognitive impairment (EBBINGHAUSS study) [68] and new-onset diabetes [69].
Moreover, the beneficial effects of lipid-lowering therapy with a non-statin agent added to high-
or moderate-intensity statin therapy have also been reported in patients with symptomatic lower
extremity peripheral artery disease (PAD), including those without prior MI or stroke [70].
Finally, a more recent meta-analysis found evidence of a significantly greater reduction of plasma
LDL-C concentrations in patients treated with evolocumab than those treated with alirocumab [66].
The third monoclonal PCSK9 inhibitor antibody, namely Bococizumab, was discontinued in
November 2016 because of neutralizing antibodies [71]. However, its effects have been described in two
large-scale cardiovascular outcomes trials, SPIRE-1 and SPIRE-2, where a total of 27,438 participants
with either a history of cardiovascular disease or familial hypercholesterolemia or high risk for
cardiovascular disease were randomized to either bococizumab subcutaneously or a matching placebo.
Despite the discontinuation, the results from both SPIRE trials confirmed the efficacy of PCSK9
inhibition in terms of very low plasma LDL-C concentrations and cardiovascular event reduction [72].
At the time of this review, new pharmacological approaches are under development to safely
inhibit PCSK9 (Table 1). The latest strategy involves the use of a small interfering RNA (siRNA) [73].
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The siRNA molecules, namely inclisiran, engage the natural pathway of RNA interference (RNAi) by
binding intracellularly to the RNA-induced silencing complex (RISC), enabling it to cleave messenger
RNA (mRNA) molecules specifically encoding PCSK9. The cleaved mRNA is degraded and thus
unavailable for protein translation, which results in decreased levels of the PCSK9 protein [74].
Table 1. PCSK9 under development.
Drugs Type Status Study
Evolocumab Monoclonal Ab Approved Proficio Program
Alirocumab Monoclonal Ab Approved Odyssey Program
Bococizumab Monoclonal Ab Discontinued Spire Program
Inclisiran Silent RNA On approval Orion 1
LGT-209 Monoclonal Ab Discontinued -
RG7652 Monoclonal Ab Phase 2 Equator
ALN-PC RNAinhibitor Phase 1 ev/Preclinical sc -
Adnectin BMS-962476 modified binding protein Phase 1 -
EGF-A peptide synthetic peptide Preclinical -
Based on the current available evidence, a PCSK9 inhibitor should be considered in specific
subsets of patients:
- Patients with ASCVD at very high risk of an adverse prognosis, with persistent elevated
plasma LDL-C concentrations despite maximally tolerated statin alone or in combination with
ezetimibe therapy.
- Patients with ASCVD at very high risk with persistent elevated plasma LDL-C concentrations,
who show intolerance to the appropriate doses of at least three statins.
- Familial hypercholesterolemia patients without clinically diagnosed ASCVD, at high
cardiovascular risk, with persistent elevated plasma LDL-C concentrations despite maximally
tolerated statin plus ezetimibe therapy [75].
4. Metabolic Effects of PCSK9 Inhibition: Beyond LDL-C Reduction
In humans, PCSK9 expression has been reported in different organs (i.e., brain, kidney,
pancreas, liver, and small intestine) [76] and cells (i.e., endothelium, smooth muscle cells, and
macrophages) [77,78], suggesting systemic and local homeostatic effects. Based on these data, blocking
PCSK9 may result in unexpected effects.
4.1. PCSK9 and Glucose Metabolism
It is known that perturbation of cholesterol metabolism may expose patients to increased risk
of diabetes, since statin treatment [79] and genetic variant of HMGCoA reductase [80] have been
associated with a higher prevalence of type 2 diabetes. Moreover, statin use and genetic inhibition of
HMGCoA reductase are associated with increased body weight [80–82], thus resulting in metabolic
syndrome and diabetes predisposition. These data seem to be confirmed by the evidence that patients
with familial hypercholesterolemia showed a lower prevalence of glucose metabolism impairment [83].
Inhibition of PCSK9 in pancreatic cells decreases cholesterol accumulation, which results in
glucose metabolism impairment and reduction of insulin secretion, thus favoring diabetes status [84].
However, contradictory data are available on this issue, since PCSK9 loss of function (LOF) is not
associated with increased risk of diabetes [85] while the PCSK9 R46L variant seems to be associated
with insulin resistance [86]. From a metabolic point of view, PCSK9, by decreasing LDL-R activity,
reduces cholesterol concentrations within the pancreatic beta-cell, finally resulting in increased
beta-cell function and insulin secretion. Moreover, the direct effect of PCSK9 on pancreatic delta-cell
leads to increased insulin secretion, thus resulting in beneficial effects on carbohydrate homeostasis.
On the other hand, PCSK9 induces insulin-regulated secretion via SREBP-1C with increased glucose,
HbA1c, and HOMA-IR index, leading to a detrimental effect on carbohydrate homeostasis, thus
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counterbalancing the beneficial effect of the other metabolic pathway. Based on these data, PCSK9
inhibition should result in a neutral effect [84].
The latest analysis of the published clinical trials, looking specifically at the new onset of diabetes,
seems to support this neutral effect [67,69]. However, the relatively short time of observation of these
studies may represent a major limitation. More recently, Cao et al. [87] published a systematic review
and meta-analysis of a total of 18 studies including 26,123 participants treated with alirocumab or
evolocumab and without diabetes. PCSK9 inhibition had no significant impact on new-onset diabetes
mellitus and glucose homeostasis, regardless of PCSK9-mAb type, participant characteristics, treatment
duration, treatment method, and differences in control treatment, thus adding new evidence for the
neutral effect of PCSK9 on glycemic control.
4.2. PCSK9 and Lipogenesis
PCSK9 not only targets LDL-R but may regulate other steps and key players in lipogenesis [76].
Recently, Verbeek et al. [88] have analyzed the lipid profile and lipoprotein subfractions by nuclear
magnetic resonance in carriers of R46L variant that are responsible for a PCSK9 LOF. The population
enrolled was part of the European Prospective Investigation into Cancer and Nutrition (EPIC) study,
designed to investigate the relationships between diet, nutritional status, lifestyle, environmental
factors, and the incidence of cancer and other chronic diseases. The data from this analysis confirm and
expand previous results [89] on the effects on other lipoproteins (such as Apolipoprotein B (ApoB), Lp
(a), secretory phospholipase A2, and Lp-PLA2( beyond the already known decrease in LDL-C plasma
concentrations. Specifically, IDL and VLDL particles were subject to a variation of −18% and −16%,
respectively. No effect on HDL-C plasma concentrations has been reported [88]. These observations
may indicate that the positive effects of PCSK9 inhibition, especially on patients at high risk, may be
related, at least in part, to the reduction of most atherogenic lipoproteins, lifelong exposure to which
is associated with an increased cardiovascular risk. It has been reported that PCSK9 circulates in the
flowing blood as lipoprotein-bound, mainly associated with ApoB within LDL and VLDL particles,
thus suggesting an involvement in another molecular pathway beyond the LDL. Confounding data
are available at the time of this article on the interaction between PCSK9 and VLDL-R, ApoE-R2, and
CD36. Because these receptors are involved in the basal and post-prandial plasma triglycerides levels,
PCSK9 may be indirectly involved in this pathway [90]. A gene silencing study with siRNA and
clinical observations in carriers of GOF and LOF variants have been performed.
Compared to patients carrying an LDL-R mutation, individuals with a PCSK9 GOF variant show
higher levels of VLDL, IDL, and triglycerides beyond the increased LDL-C plasma concentrations.
On the other hand, individuals with a PCSK9 LOF variant, especially the R46L, show a reduction in all
ApoB-containing lipoproteins [90], and attenuated levels of fasting and postprandial triglycerides [91].
Based on these observations, a putative role of PCSK9 in the clearance of triglyceride-rich lipoproteins
(TGRLs) may be postulated. Similar results have been obtained by inhibiting PCSK9 via gene silencing
or viral transfection, thus suggesting a non-direct effect of PCSK9 on triglyceride metabolism [90].
Moreover, a recent study confirms that Alirocumab reduces ApoB levels in both IDL and LDL, most
likely due to increased LDL degradation [92]. It is known that ApoB turnover is strongly influenced by
the uptake of lipoproteins containing ApoB, mediated by LDL-R [93]. Results from the FOURIER trials
indicate that PCSK9 inhibition is associated with a mild–moderate reduction in triglyceride levels [59].
The biological mechanism underlying this effect may include several pathways beyond the increased
LDL-R activity that are associated with the increased catabolism of TGRLs [94]. It is known that PCSK9
modulates lipoprotein assembly and secretion by the intestine and the liver and affects TGRL and
fatty acid uptake in peripheral tissues via expression of the very-low-density lipoprotein receptor
(VLDL-R), the ApoE2 receptor, and the CD36 receptor [16,76]. The receptor for VLDL modulates the
extra-hepatic metabolism of TGRLs in concert with lipoprotein lipase, thus contributing to the delivery
of fatty acids to these peripheral tissues, especially in the heart, skeletal muscle, and adipose tissue,
where it is highly expressed.
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However, despite the reduction in triglycerides (up to 17.3%), ApoB (up to 56%) and the positive
outcomes in the clinical trials testing PCSK9 inhibition by both monoclonal antibodies, alirocumab and
evolocumab, the clinical impact of the non-LDL cholesterol concentrations on CV risk remain unclear.
Summarizing, the lower plasma triglyceride concentrations and the decreased postprandial
lipemia may be the results of the following mechanisms [94]: (a) reduced intestine ApoB48 production,
leading to decreased chylomicron secretion; (b) increased ApoB degradation, resulting in reduced
ApoB-rich lipoproteins; (c) increased chylomicrons, chylomicron remnants, and VLDL remnants
clearance via increased LDL-related protein 1 activity and CD36 scavenger receptor upregulation; (d)
VLDL receptors and ApoE receptors.
4.3. PCSK9 and HDL Particles
Finally, the available clinical trials (OSLER [95], ODYSSEY Long Term [96], and FOURIER [65])
indicate that PCSK9 inhibition may also affect HDL metabolism. A modest increase in plasma HDL-C
and apoA1 concentrations (estimated at less than 10%) has been reported. This effect may be the result
of two potential mechanisms: (a) the reduced number of LDL particles leads to a decreased transfer
of cholesterol from HDL to LDL particles [97,98]; (b) the blockage of PCSK9 reduces cholesterol ester
transfer protein (CETP) activity, thus decreasing heteroexchange of lipids between TGRLs and HDL
particles [99].
5. “Very Low Is Better”: End of Story?
The progression of pharmacological modulation of lipid metabolism and the available data on
safety and efficacy of the current strategies indicate that more ambitious targets in terms of lipid lowering
can be achieved. Randomized clinical trials published to date clearly showed that PCSK9 inhibitors
may result in plasma LDL-C concentrations lower than 50 mg/dL easily with no safety concern [100].
More interestingly, a recent report from Ference et al. quantified the reduction of cardiovascular
events in about 20% per decrease of 1.00 mmol/L (39 mg/dL) in plasma LDL-C concentrations [101].
These effects mediated by PCSK9 inhibitors are independent and additive with statins. Thus, taking into
account the fact that inhibition of PCSK9 results in a strong reduction of plasma LDL-C concentrations,
the benefit expected will be higher, especially in patients with an elevated baseline value.
Based on these results, the latest guidelines from the American Association of Clinical
Endocrinologists and American College of Endocrinology [102] identify an “extreme risk” group
(Table 2a), beyond the very high-risk group already defined in the European Society of Cardiology
Guidelines 2016 [103] (Table 2b), characterized by progressive atherosclerotic cardiovascular disease,
including unstable angina that persists after achieving an LDL-C less than 70 mg/dL, or established
clinical ASCVD with diabetes, stage 3 or 4 CKD, and/or HeFH, or in those with a history of premature
ASCVD (<55 years of age for males or <65 years of age for females) in which a LDL-C goal of less than
55 mg/dL is recommended. The goal of 30 mg/dL, as indicated in most of the PCSK9 inhibitors clinical
trials, is desirable.
However, how safe it is to go “very low” remains to be elucidated [104] and will be a matter
for the long-term outcomes study to determine in the next few years. On this safety concern,
some epidemiological studies available to date indicate a different association between cholesterol
plasma concentration and neoplastic risk, hemorrhagic stroke, depression and anxiety, and nervous
and immune system dysfunction. Specifically, decreased plasma LDL-C concentrations have been
associated with increased cancer risk [105]. In a study from Benn et al. including participants from the
Copenhagen City Heart Study and the Copenhagen General Population Study, low plasma LDL-C
concentrations were firmly associated with increased cancer risk, but genetically decreased LDL-C
was not [106]. Whether this association is causal remains unclear. Low LDL-C plasma concentrations
may be a consequence, rather than a cause, of the neoplastic disease, thus may not cause cancer per se.
Pre-specified clinical trials designed to address this safety issue are warranted.
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Abstract: The most important function of high density lipoprotein (HDL) is its ability to remove
cholesterol from cells and tissues involved in the early stages of atherosclerosis back to the liver for
excretion. The ATP-binding cassette transporters ABCA1 and ABCG1 are responsible for the major
part of cholesterol efflux to HDL in macrophage foam cells. Thus, promoting the process of reverse
cholesterol transport (RCT) by upregulating mainly ABCA1 remains one of the potential targets
for the development of new therapeutic agents against atherosclerosis. Growing evidence suggests
that posttranscriptional regulation of HDL biogenesis as well as modulation of ABCA1 expression
are under the control of several genetic and epigenetic factors such as transcription factor (TFs),
microRNAs (miRNAs) and RNA-binding proteins (RBPs).These factors may act either individually
or in combination to orchestrate ABCA1 expression. Complementary to our recent work, we propose
an exploratory model for the potential molecular mechanism(s) underlying epigenetic signature of
ABCA1 gene regulation. Such a model may hopefully provide the basic framework for understanding
the epigenetic regulation of RCT and contribute to the development of novel therapeutic strategies to
alleviate the burden of cardiovascular diseases (CVD).
Keywords: ABCA1; HDL; miRNA; circular RNA; gene expression; RNA-binding proteins; reverse
cholesterol transport; cardiovascular diseases
1. Introduction
Based on the general consensus that HDL protects against atherosclerotic CVD, several
attempts have been made to design drugs that raise HDL cholesterol (HDL-C) levels or enhance
its cardioprotective function. However, several prospective HDL-C-raising trials have failed to
demonstrate improved efficacy for major adverse cardiovascular outcomes. In this prospect, there
are continuous efforts to increase HDL functionality to enhance RCT and potentially achieve further
cardiovascular event reduction.
Over the last decades, genetic breakthroughs have revolutionized cardiovascular research by
providing opportunities to elucidate novel molecular mechanisms underlying HDL biogenesis and
RCT pathways. Some preclinical and clinical studies have shown that apoA-I Milano, a naturally
occurring mutant of ApoA-I (Arg173Cysteine) has beneficial athero-protective and anti-inflammatory
effects [1]. Furthermore, research has suggested that the expression of genes involved in the RCT
combines several complex regulatory networks that are controlled by at least two types of trans-factors:
transcription factors (TFs) in the nucleus and posttranscriptional epigenetic factors that bind to
cis-regulatory RNA elements mostly located in the 3′UTR of their target mRNAs. Epigenetic factors
including miRNAs and RBPs have been shown to be associated with several pathophysiological
Diseases 2018, 6, 34; doi:10.3390/diseases6020034 www.mdpi.com/journal/diseases91
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conditions. For instance, the dysregulation of miRNAs has been associated with the disruption
of multiple gene networks leading to metabolic disorders including diabetes, obesity, metabolic
syndrome and atherosclerosis [2,3]. This clearly indicates that beyond the existing therapies, advance
in epigenetics mechanisms could offer additional opportunities to develop novel treatment strategies
for atherosclerosis. In this regard, attempts have been made to develop Apabetalone (RVX-208) as the
first epigenetic approach to treat CVD. In recent clinical trials such as SUSTAIN and ASSURE, RVX-208,
an orally active molecule has been shown to increase plasma apoA-I, HDL-C (pre-beta and alpha-HDL),
and enhance the ability of serum to efflux cholesterol via ABCA1, ABCG1, and scavenger receptor
class B type I (SR-BI)-dependent pathways [4]. RVX-208 increases apoA-I transcription through an
epigenetic mechanism by inhibiting the bromodomain and extra-terminal domain (BET) protein 4
(BRD4) [5]. Most importantly, emerging evidence has suggested that miRNAs act as a novel class of
epigenetic regulators of RCT and HDL-C from synthesis to clearance, and thus contributing remarkably
to the pathogenesis of atherosclerosis [6]. Hence, understanding epigenetic mechanisms that control
RCT genes network, mainly ABCA1 gene that is involved in the initiation of this process, may bring
insights into novel therapeutic approaches for treating atherosclerotic vascular disease.
2. Discussion
ABCA1 is a key mediator of cholesterol efflux to lipid-poor apolipoprotein A-1. Several studies
have confirmed that compromised ABCA1 activity leads to accelerated and early atherogenesis.
As summarized in our recent paper [6], the RCT gene network is a complex process highly controlled
at both transcriptional and posttranscriptional levels. Herein, we consider the ABCA1 gene, for which
some experimental knowledge is available both at the transcriptional and posttranscriptional levels,
as an example to illustrate potential epigenetic mechanisms driving the regulation of RCT. We propose
a hypothetical model for the potential dynamic interplay between different genetic and epigenetic
regulators that may serve to regulate ABCA1 gene enabling the cell to respond to different environment
changes (Figure 1). However, all proposed axes of interaction, if they occur, need to be experimentally
validated in different models.
At the transcriptional level, several nuclear receptors including peroxisome proliferator-activated
receptors (PPARs), liver X-receptor (LXR), and farnesoid X receptor (FXR), have been shown
to influence lipid metabolism along with genes involved in RCT pathway including ABCA1.
Unfortunately, despite the effectiveness of these nuclear receptors in preclinical studies, their translation
to human clinical trials is still facing many challenges.
At the posttranscriptional level, the 3′-UTR of ABCA1 gene has been shown to be directly targeted
by multiple miRNAs including miR-33, miR-758, miR-145, miR-27, miR-144, miR-26 and miR-106,
which lead to cholesterol efflux and HDL-C levels repression [6]. In addition to miRNAs, RNA-binding
proteins (RBPs) are also known to bind to AU-rich elements (AREs) in the 3′UTR of many genes, and
thereby modulate their expression by increasing or decreasing mRNAs’ translation and/or stability.
With respect to ABCA1, human antigen R (HuR), an RBP, has been reported to bind to the 3′-UTR
of this transporter and increase its expression by enhancing protein translation [7]. Based on this
information, it would be tempting to suggest the existence of a possible regulatory relationship between
miRNAs and RBPs that could influence ABCA1 expression. In this context, specific miRNAs and RBPs
may act via cooperation/competition to directly or indirectly regulate gene expression. Furthermore,
post-translational modifications of RBPs, including their phosphorylation and methylation, provide
additional layers of complexity, as they control RNA-binding, function and localization [8]. Therefore,
phosphorylation and nuclear transit of RBPs could be another possible mechanism to influence
RBP-mediated regulation of ABCA1 gene expression as suggested in a previous study [9]. In addition
to these potential mechanisms, certain miRNA species may also control the expression of other
important epigenetic regulators such as DNA methyltransferases and histone deacetylases. Conversely,
DNA/RNA methylation and histone modification may contribute to the regulation of these miRNAs.
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Figure 1. Schematic representation of proposed scenarios for the mechanisms by which ABCA1 gene
expression is regulated. Various factors including nutrition, state diseases, stress and inflammation
can alter epigenetic ABCA1 gene regulation in different cells mainly macrophages and hepatocytes (1).
At the transcriptional level, ABCA1 gene expression is regulated by key nuclear receptors including LXR
family and their heterodimeric partners, retinoic acid receptors (RXR) via functional LXREs (2). At the
post-transcriptional level, miRNAs and RBPs (Hur) cooperate/compete for target binding regulation
(3). miRNAs and TFs may cooperate to tune gene expression by forming feedback or feedforward loops
(4) and (5). CircRNAs may also be part of the interplay by their potential interaction with TFs, miRNAs
and RBPs (2), (4), (6) and (7). Finally, the proposed interplay between TFs-miRNAs-RBPs-CircRNAs
could be taken into consideration while elucidating epigenetic mechanisms regulating the first step of
RCT gene network.
As is true for protein-coding genes, the expression of miRNAs is also under the control of
numerous transcription factors. Aberrant regulation of miRNAs by TFs can cause phenotypic
variations and diseases. As an example, miR-26, known to directly target the ABCA1 3′-UTR, thereby
repressing cholesterol efflux and HDL-C levels, has been shown to be inhibited in cells treated with
LXR agonists [10]. Moreover, the activation of LXR has been associated with an increase in miR-144
and ABCA1 expression to fine-tune RCT by macrophages [11]. On the other hand, miRNAs/TFs
feedback-loop regulation may occur and represent another possible mechanism involved in the
regulation of the RCT gene networks [12]. As an example of the TFs–miRNA regulatory network,
RXRα has been reported to be regulated by miRNAs including miR-128-2 [13], while other miRNAs
have been shown to regulate the expression and activity of different TFs such PPARs. Hence, it is
reasonable to assume the existence of a possible cross-talk between TFs and miRNAs that could
modulate ABCA1 gene and RCT circuit. However, such mechanisms of regulation are still not well
defined and could represent an important future area of research.
Circular RNAs (circRNAs), a class of RNAs with the linking of 3′ and 5′ ends, are predicted to
function as robust transcriptional and posttranscriptional regulators of gene expression. Evidence
is arising that some circRNAs might regulate miRNA function as microRNA sponges. Relevant
information in this respect can be provided by the web tool CircInteractome, freely available at http:
//circinteractome.nia.nih.gov. This new database has been developed for exploring circRNAs and their
interacting proteins and microRNAs [14]. Further studies have suggested that circRNA-miRNA-mRNA
axes play a prominent role in different pathologies including CVD [15]. Some circRNAs have been
predominantly localized in the nucleus where they can directly promote host-gene transcription
through interaction with RNA polymerase II (pol II) in the promoter region of genes. Furthermore,
these RNAs may interact with TFs to influence various diseases [16].
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Because no data are yet available regarding the impact of circRNAs on lipid homeostasis and HDL
biogenesis, this has prompted us to propose a model integrating TFs, miRNAs, RBPs and CirRNAs
into the ABCA1 regulatory gene network (Figure 1). However, we are aware that certain circuits of this
model are much more difficult to directly translate in vivo mostly due to the complexity of several
highly connected pathways with feedback and feedforward loops. Thus, to validate the proposed
epigenetic transcriptional and post-transcriptional mechanisms for ABCA1 gene expression regulation,
future well-designed in vivo experimental studies combined with high-throughput sequencing and
bioinformatic data are required.
3. Conclusions and Perspectives
Emerging research suggests that deregulated miRNAs can impact RCT gene networks, mainly
ABCA1 gene. These observations have generated a renewed interest in novel targets for epigenetic
regulators that may pave the way for establishing novel strategies to raise functional HDL and promote
RCT. However, since the field of epigenetic regulation by small RNAs is still in its infancy, there are only
a few experimentally validated data associating the dysregulation of miRNAs with genes involved in
the HDL biogenesis and RCT. Our proposed model (Figure 1) for potential epigenetic regulation of
ABCA1 is expected to be translated into specific questions and hypothesis which may benefit further
research in this area. However, one of the greatest challenges one may confront here is how to fully
gain knowledge from the potential interplay and/or cross-talk between various miRNAs and other
cellular regulatory factors controlling specific pathway(s) of cholesterol removal from cells and how all
these networks can shape a physiological function in both normal and pathological cells in response to
a behavior or a stimulus. To answer these questions, more focus should be given to the integration of
computational approaches such as systems biology and molecular networks modeling in combination
with high-throughput experiments to provide a list of potential miRNA target genes involved in the
RCT process. This might help us to better understand the consequences of the complex interplay of
miRNAs with other epigenetic regulators on ABCA1 gene and possibly other relevant genes involved
in RCT regulation.
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Abstract: The rapidly expanding field of bioactive lipids is exemplified by the many sphingolipids,
which are structurally and functionally diverse molecules with significant physiologic functions.
These sphingolipids are main constituents of cellular membranes and have been found associated
with plasma lipoproteins, and their concentrations are altered in several metabolic disorders such as
atherosclerosis, obesity, and diabetes. Understanding the mechanisms that regulate their biosynthesis
and secretion may provide novel information that might be amenable to therapeutic targeting in the
treatment of these diseases. Several sphingolipid synthesis genes have been targeted as potential
therapeutics for atherosclerosis. In recent years, significant progress has been made in studying the
role of microRNAs (miRNAs) in lipid metabolism. However, little effort has been made to investigate
their role in sphingolipid metabolism. Sphingolipid biosynthetic pathways involve various enzymes
that lead to the formation of several key molecules implicated in atherosclerosis, and the identification
of miRNAs that regulate these enzymes could help us to understand these complex pathways better
and may prove beneficial in alleviating atherosclerosis.
Keywords: atherosclerosis; ceramides; lipids; lipoproteins; miRNA; sphingolipids; sphingomyelin
1. Introduction
High plasma lipid levels are major risk factors for several cardiovascular and metabolic disorders
such as atherosclerosis, obesity, and diabetes. Some of the most important risk factors for atherosclerosis
are the circulating levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
cholesterol [1,2]. Besides traditional risk factors, changes in sphingolipids may contribute to the
pathogenesis of cardiovascular disease (CVD) [3,4]. Sphingolipids are a class of lipids that contain
a sphingoid base, an aliphatic amino alcohol including sphingosine. Sphingoid bases such as
dihydrosphingosine and sphingosine are the fundamental building blocks of all sphingolipids.
Sphingolipids are biologically active cell components that regulate cellular processes and play an
important role in signal transduction and cellular stress responses. The synthesis and degradation
of sphingolipids, which serve as both structural lipids as well as signaling molecules, are regulated
to maintain homeostasis [3]. Sphingolipids are either derived from other sphingolipids through
catabolism via the salvage pathway or synthesized de novo in the endoplasmic reticulum [5].
Ceramide is a simple sphingolipid composed of sphingosine and a fatty acid. Ceramide constitutes the
hydrophobic backbone and serves as the key precursor for the de novo synthesis of other biologically
active complex sphingolipids (Figure 1) [6]. It represents a nodal point in the sphingolipid de
novo pathway. It can be glycosylated or acquire a polar head group to form glycosphingolipids
or sphingomyelin (SM), respectively [3]. It can also be reversibly degraded to form sphingosine which
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in turn can be phosphorylated by sphingosine kinase (SPK) to form sphingosine-1-phospate (S1P).
Once synthesized, sphingolipids can be transported to plasma lipoproteins [7] or remain associated
with cellular membranes. An imbalance of sphingolipid levels in plasma and tissue is associated with
several metabolic diseases including atherosclerosis [4].
Figure 1. Schematic representation of miRNAs implicated in the synthesis of some key sphingolipid
molecules. The figure is representative of some key enzymatic steps involved in sphingolipid
biosynthetic pathways that are known to be regulated by various miRNAs (dotted rectangles).
Enzymes with asterisks (dotted ovals) may be potential targets for other miRNAs that need to be
identified. Increased levels of ceramides, sphingomyelin and glucosylceramide (red arrows) and
decreased levels of sphingosine-1-phosphate (green arrow) have been implicated in atherosclerosis.
The identification of novel miRNAs that regulate sphingolipid metabolism may be a potential
therapeutic target to treat atherosclerosis. Abbreviations: SPT, serine palmitoyl transferase; CDase,
ceramidase; CS, ceramide synthase; SPK, sphingosine kinase; S1PP, sphingosine-1-phosphate
phosphatase; SMS, sphingomyelin synthase; SMase, sphingomyelinase; GCS, glucosylceramide
synthase; GCDase, glucosylceramidase.
An increased plasma SM level has been proposed as an independent risk factor for coronary
heart disease and has been shown to be associated with increased atherosclerosis in humans [8].
A reduction in SM levels in sphingomyelin synthase (SMS) knockout mice is known to decrease
atherosclerosis [9,10]. Like SM, increased plasma and aortic ceramide levels are also associated with
an increased risk of CVD [11]. Genetic deficiency or the inhibition of type 2-neutral sphingomyelinase
(nSMase2), a key enzyme in sphingolipid metabolism, has been shown to decrease atherosclerosis in
ApoE knockout mice by reducing inflammatory responses due to a decrease in ceramide levels [12].
Furthermore, plasma glycosphingolipid concentrations have been reported to be elevated in patients at
increased risk of atherosclerosis [13]. The pharmacological inhibition of glucosylceramide synthase that
is responsible for the synthesis of glucosylceramides has been reported to ameliorate atherosclerosis in
ApoE knockout mice and rabbits [14]. In contrast to ceramide, glycosphingolipid, and SM, plasma
S1P is believed to be cardioprotective [3]. Regulation of the interconvertible sphingolipid metabolites,
ceramide and S1P, and their opposing signaling pathways may determine the net biological effect,
a concept referred to as the “sphingolipid rheostat”. Plasma S1P levels significantly decrease after
myocardial infarction [15] and increase in patients after percutaneous coronary intervention [16]. It is
believed that S1P bound to HDL may predict the severity of coronary heart disease [17]. Recently, it has
been shown that apoM acts as a carrier and modulator of S1P that largely affects its homeostasis [18].
Lipid metabolism is a multi-faceted process that involves synthesis, accumulation, secretion,
distribution to various tissues, degradation as well as excretion. Lipid metabolism is regulated by
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finely modulating a set of rate-limiting enzymes and transporters based on the needs of the cells [19].
A variety of cellular regulators including transcription factors that are involved in its synthesis and
degradation are responsible for maintaining lipid homeostasis. The discovery that the cellular lipid and
lipoprotein metabolism is targeted by miRNAs has provided new insight into the molecular mechanism
of the pathogenesis of atherosclerosis, diabetes and obesity [20]. This has led to the exploitation of
miRNAs as regulators of lipid metabolism with subsequent potential use in the treatment of lipid
metabolism-related disorders [21,22]. This mini-review provides an overview of what is known about
the regulation of lipid metabolism in general and sphingolipid metabolism in particular by miRNAs
and emphasize their role in atherosclerosis.
2. Regulation of Lipid and Lipoprotein Metabolism by miRNAs
miRNAs are a class of small ~22-nucleotide long non-coding sequences which
post-transcriptionally regulate gene expression to modulate a wide spectrum of biological
processes [23,24]. They act as negative post-transcriptional regulators of gene expression [21,22] and
have been proposed to regulate the expression of more than half of the human genes via controlling
the expression of mRNA targets. miRNAs repress protein expression by mRNA destabilization and/or
translational inhibition after binding the complementary sequences in the 3′ untranslated region
(3′-UTR) of target mRNAs via seed sequences (Table 1) [25]. Individual miRNAs can target several
mRNAs that are often connected in the same metabolic pathway [26]. Moreover, several miRNAs may
regulate a single mRNA, thus enabling a fine-tuning of the targeted mRNA expression, to influence
the regulation of cellular events [23,26]. Dysregulation of miRNAs has been correlated with disease
pathogenesis [27]. Furthermore, miRNAs can be released from cells as exosomes in many body fluids
and may serve as noninvasive biomarkers of diseases [28].
Table 1. Predicted seed sequence, target genes and tissues of miRNAs implicated in lipid and
sphingolipid metabolism.






miR-144 UAUGACA ABCA1 Liver
miR-758 CAGUGUU ABCA1 Liver
miR-26 AUGAACU ABCA1 Liver
miR-106b CGUGAAA ABCA1 Liver
miR-27 AUUCGAG SR-B1 Liver
miR-185 AGAGAGG SR-B1 Liver
miR-96 CACGGUU SR-B1, ABCA1 Liver
miR-223 UUGACUG SR-B1 Liver
miR-30c CAAAUG MTTP, LPGAT1, ELOVL5,STARD3, MBOAT1 Liver
miR-128-1 GCCGGGG LDLR Liver
miR-148 ACGUGAC LDLR, ABCA1 Liver
miR-122 UGUGAGG FASN, SCD1, ACLY, ACC2 Liver
miR-155 CGUAAU LXRα Liver
miR-574 GUGUGAG CerS Multiple human cancer cells
miR-9 UGGUUUC SPTLC1, SPTLC2 Primary astrocytes
miR-29a UUUAGUC SPTLC1, SPTLC2 Primary astrocytes
miR-29b-1 UUUGGUC SPTLC1, SPTLC2 Primary astrocytes
miR-101 CUAUUGA SPK Colorectal cancer cells
* Conserved seed sequence for each miRNA was predicted by using TargetScan Human database (http://www.
targetscan.org/vert_72/).
Over the past few decades, the role of miRNAs in controlling the cellular lipid and lipoprotein
metabolism has been extensively studied. A large array of miRNAs participate in the lipid and
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lipoprotein metabolism by targeting enzymes and proteins that are involved in these metabolic
pathways. This discovery has provided new insight into the biology and pathophysiology of CVD
such as atherosclerosis [20,29]. Higher levels of HDL are inversely correlated with developing CVD.
A number of miRNAs, of which miR-33a and miR-33b are the most well-studied, regulate HDL
metabolism and control circulating cholesterol levels by regulating HDL synthesis, efflux and
clearance [30,31]. miR-33a and miR-33b target multiple genes that regulate cholesterol efflux, which is
regarded as an important cholesterol regulatory mechanism [32]. Studies in various animal models
and cell lines have confirmed that miR-33 targets ATP-binding cassette (ABC) transporter A1, ABCA1,
by binding to 3′-UTR of ABCA1 via seed sequence to regulate cholesterol metabolism by attenuating
circulating HDL levels and thereby decreasing cholesterol efflux to apolipoprotein A1 (apoA1) [30,32].
Conversely, the silencing of miR-33 by using lentiviral expression clone containing anti-sense to
miR-33 in experimental animal models generally results in increased hepatic expression of ABCA1 and
enhanced cholesterol efflux to ApoA1, thus increasing circulating HDL levels [32].
In vivo delivery of other miRNAs such as miR-144, miR-758, miR-26, and miR-106b by using
either adenoviral or lentiviral expression clones has been shown to have similar results of decreased
ABCA1 expression and reduced levels of circulating HDL-cholesterol [33]. The post-transcriptional
repression of scavenger receptor class B type 1 (SR-B1) by miR-27, miR-185, miR-96, and miR-223
has also been shown to reduce selective HDL-cholesterol uptake [33]. Reverse cholesterol transport
decreases cholesterol levels in peripheral macrophages and in atherosclerotic plaques to increase
plaque stability and inhibit atherosclerosis progression [34]. These studies show that HDL metabolism
provides a potential therapeutic target to treat atherosclerosis by regulating ABCA1 via miRNAs.
Besides the HDL metabolism, reports have shown that miRNAs such as miR-30c, miR128-1,
or miR-148a are also involved in controlling plasma LDL-cholesterol levels by regulating genes
involved in cholesterol biosynthesis, very low-density lipoprotein (VLDL) secretion, and hepatic
LDL receptor expression [30]. Recently, it was shown that miR-30c targets microsomal triglyceride
transfer protein (MTTP) to regulate VLDL biogenesis and modulate lipid substrate availability for
VLDL assembly by targeting genes involved in lipid biosynthesis such as lysophosphatidylglycerol
acyltransferase 1 (LPGAT1), ELOVL fatty acid elongase 5 (ELOVL5), stAR related lipid transfer
domain containing 3 (STARD3), and membrane bound O-acyltransferase domain containing 1
(MBOAT1) [35]. Inhibition of miR-122 has been shown to increase fatty acid oxidation and inhibit lipid
synthesis genes such as fatty acid synthase (FASN), steroyl-coA desaturase 1 (SCD1), ATP citrate
lyase (ACLY) and acetyl-coA carboxylase 2 (ACC2) and thereby reduce the availability of lipid
substrates for VLDL biogenesis [36]. Similarly, inhibition of miR-33a and miR-33b expression
in the liver is shown to increase fatty acid oxidation by increasing the expression of carnitine
O-octanoyltransferase (CROT), carnitine palmitoyltransferase 1A (CPT1A) and hydroxyacyl-CoA
dehydrogenase trifunctional multienzyme complex subunit beta (HADHB), and decrease its synthesis
by reducing the synthesis of FASN, ACLY, sterol regulatory element binding factor 1 (SREBF1) and
acetyl-CoA carboxylase alpha (ACACA) to reduce VLDL secretion in the circulation [37]. Furthermore,
reports have suggested that increased expression of miR-155 in liver macrophages regulates fatty acid
metabolism by directly targeting liver X receptor alpha (LXRα) and thereby reducing hepatic lipid
accumulation [38]. These studies indicate that miRNAs exert their regulatory impacts at different
levels of lipoprotein biosynthesis.
3. Regulation of Sphingolipid Metabolism by miRNAs
Sphingolipids have been recognized to regulate distinct biological functions beyond their role as
structural membrane components. Within the past few decades, significant progress has been made
toward understanding the role of sphingolipid pathways for atherosclerosis. The role of miRNAs
to regulate sphingolipid metabolism has not been widely studied. There are only a few limited
studies, done mostly in cancer cell lines, that have investigated the role of miRNAs in the regulation
of enzymes involved in sphingolipid biosynthetic pathways (Figure 1) [39–41]. Ceramide is a central
99
Diseases 2018, 6, 82
molecule in sphingolipid metabolism [6] which is generated either through de novo pathway or salvage
pathway [5]. Ceramide acts as a signaling molecule, regulating many cellular responses and functions
that may be involved in molecular mechanisms of CVD. The generation of ceramide can be significantly
enhanced in certain inflammatory conditions such as atherosclerosis [12]. Ceramide is synthesized
by a family of six ceramide synthases (CerS), each of which synthesizes ceramide with distinct acyl
chain lengths. An alternatively spliced variant of ceramide synthase, CerS1-2, which is responsible for
synthesizing C18-ceramide, is a target for miR-574-5p [41]. The knockdown of miR-574-5p expression
has been shown to increase C18-ceramide levels in multiple human cancer cell lines [41].
Serine-palmitoyl transferase (SPT), which converts L-serine and palmitoyl-CoA to
3-ketosphinganine, is the first and rate-limiting enzyme of the de novo biosynthetic pathway
of ceramide and SM. SPT has been implicated in the pathogenesis of atherosclerosis and its modulation
has been suggested to be a novel therapeutic target in atherosclerosis [42]. Several studies have
shown that the pharmacological targeting of SPT through the inhibition with myriocin protects from
atherosclerosis in ApoE knockout mice [42–45]. Myriocin has been shown to reduce the levels of not
only ceramide but other sphingolipids downstream of ceramide, such as SM, glucosylceramide and
S1P as well [42,44,45]. Similar to pharmacological intervention, targeting the enzymes involved in
sphingolipid biosynthesis through miRNAs may be a potential therapeutic intervention for alleviating
atherosclerosis. Serine-palmitoyl transferase long chain base subunit 1 (SPTLC1) and 2 (SPTLC2) are
the subunits of SPT and one study found a negative correlation between the expression levels of
miR-137/-181c and SPTLC1 [40]. Transfection of primary rat astrocytes with miR-137 and miR-181c
showed a significant suppression of the endogenous SPTLC1 expression and cellular ceramide levels.
On the other hand, anti-miR-137 and anti-miR-181c significantly increased the endogenous SPTLC1
expression and cellular ceramide levels. In the same study, a negative correlation was also found
between miR-9/-29a/b-1 and SPTLC2 protein expression in sporadic Alzheimer’s disease brains.
Again, the transient transfection of primary rat astrocytes with miR-9, miR-29a, and miR-29b-1
significantly suppressed the endogenous SPTLC2 and cellular ceramide levels and their antagomirs
significantly enhanced the expression of SPTLC2 and cellular ceramide levels.
Finally, plasma S1P levels have been reported to be lower in CVD patients, suggesting its
involvement in the pathogenesis of atherosclerosis [15]. Sphingosine kinase is involved in the
conversion of sphingosine to S1P that have distinct intracellular and extracellular functions [46,47].
Exogenously expressed miR-101 has been shown to down-regulate SPK mRNA and protein expression
in colorectal cancer cells [39]. The downregulation of SPK has been shown to result in increased
ceramide levels in miR-101 expressed cells. On the other hand, the expression of SPK was enhanced by
treating HT-29 human colorectal adenocarcinoma cells with the antagomiR-101 that resulted in lower
levels of ceramide [39].
4. Conclusions
Significant advances have been made in studying the role of miRNAs in lipid metabolism.
However, there is a paucity of information on their role in sphingolipid metabolism.
Several sphingolipid synthesis genes have been targeted as potential therapeutics for various metabolic
disorders, such as atherosclerosis. Sphingomyelin synthase, sphingomyelinase, and glucosylceramide
synthase are some of the key enzymes that have been implicated in atherosclerosis [9,10,12,14]
(Figure 1). It is likely that studying the panel of miRNAs that regulate sphingolipid metabolism
could help us to understand these pathways better, and the modulation of these pathways may prove
to be a potential therapeutic strategy. There are only a few studies that have reported the regulation
of enzymes involved in sphingolipid biosynthetic pathways by certain miRNAs [39–41], and most of
these studies are targeted towards ceramide synthesis in various cancer cell lines [39,41]. However,
there is a lack of information on whether miRNAs regulate sphingolipid metabolism in vivo and
thereby influence atherosclerosis. Based on the genetic deficiency and pharmacological inhibition
studies [9,10,12,14,42], we predict that the regulation of some of the key enzymes in sphingolipid
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biosynthetic pathways by miRNAs may be useful and a potential therapeutic strategy to alleviate
atherosclerosis. Therefore, more focused studies are needed to identify and understand the role of
various miRNAs in regulating sphingolipid metabolism.
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ABCA1 ATP-binding cassette transporter A1
ACACA acetyl-CoA carboxylase alpha
ACC2 acetyl-coA carboxylase 2
ACLY ATP citrate lyase
ApoA1 apolipoprotein A1
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CPT1A carnitine palmitoyltransferase 1A
CROT carnitine O-octanoyltransferase
CVD cardiovascular disease
ELOVL5 ELOVL fatty acid elongase 5
FASN fatty acid synthase
HADHB hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta
HDL high-density lipoprotein
LDL low-density lipoprotein
LPGAT1 lysophosphatidylglycerol acyltransferase 1
LXRα liver X receptor alpha
MBOAT1 membrane bound O-acyltransferase domain containing 1
miRNAs microRNAs
MTTP microsomal triglyceride transfer protein






SPTLC1 serine-palmitoyl transferase long chain base subunit 1
SPTLC2 serine-palmitoyl transferase long chain base subunit 2
SR-B1 scavenger receptor class B type 1
nSMase2 type 2-neutral sphingomyelinase
SREBF1 sterol regulatory element binding factor 1
STARD3 stAR related lipid transfer domain containing 3
3′-UTR 3′ untranslated region
VLDL very low-density lipoprotein
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